

<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="vnda-20190630.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:href="vnda-20190630.xsd#AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="vnda-20190630.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:href="vnda-20190630.xsd#AccumulatedOtherComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:href="vnda-20190630.xsd#AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:href="vnda-20190630.xsd#AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:href="vnda-20190630.xsd#BusinessOrganizationAndPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:href="vnda-20190630.xsd#BusinessOrganizationAndPresentationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="vnda-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesResearchAndDevelopmentAndMarketingAgreementsDetails" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesResearchAndDevelopmentAndMarketingAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesSummaryOfNoncanellableLongTermContractualCashObligationsDetail" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesSummaryOfNoncanellableLongTermContractualCashObligationsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:href="vnda-20190630.xsd#CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vnda-20190630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="vnda-20190630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vnda-20190630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="vnda-20190630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:href="vnda-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vnda-20190630.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:href="vnda-20190630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:href="vnda-20190630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:href="vnda-20190630.xsd#EarningsPerShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:href="vnda-20190630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:href="vnda-20190630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="vnda-20190630.xsd#FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:href="vnda-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:href="vnda-20190630.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#IntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:href="vnda-20190630.xsd#IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:href="vnda-20190630.xsd#IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="vnda-20190630.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:href="vnda-20190630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:href="vnda-20190630.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:href="vnda-20190630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Leases" xlink:href="vnda-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:href="vnda-20190630.xsd#LeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" xlink:href="vnda-20190630.xsd#LeasesLeaseAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:href="vnda-20190630.xsd#LeasesMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" xlink:href="vnda-20190630.xsd#LeasesMaturitiesUnderAsc840Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:href="vnda-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:href="vnda-20190630.xsd#LegalMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:href="vnda-20190630.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:href="vnda-20190630.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:href="vnda-20190630.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock" xlink:href="vnda-20190630.xsd#PublicOfferingOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetail" xlink:href="vnda-20190630.xsd#PublicOfferingOfCommonStockDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:href="vnda-20190630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:href="vnda-20190630.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:href="vnda-20190630.xsd#StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:href="vnda-20190630.xsd#StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:href="vnda-20190630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:href="vnda-20190630.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnda-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="vnda-20190630.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:href="vnda-20190630.xsd#SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnda-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:href="vnda-20190630.xsd#SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSupplementalCashFlowsInformationDetails" xlink:href="vnda-20190630.xsd#SummaryOfSignificantAccountingPoliciesSupplementalCashFlowsInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vnda-20190630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Tables" xlink:href="vnda-20190630.xsd#Tables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4C20833BAD800CF7FB40DDB18696701D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_26075CFDD237DE5561F5DDB186967429" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4C20833BAD800CF7FB40DDB18696701D" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_26075CFDD237DE5561F5DDB186967429" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4BAC9B3092DDC473BEF22560036E1AB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4BAC9B3092DDC473BEF22560036E1AB6" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_AccruedResearchAndDevelopmentExpense" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_89F91FA22B347967BE622560036DCA74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:to="loc_vnda_AccruedResearchAndDevelopmentExpense_89F91FA22B347967BE622560036DCA74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_0538BB96378822AAF7402560036E8160" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_0538BB96378822AAF7402560036E8160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_E9C8F1EED60EA81B268C2560036E3944" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_E9C8F1EED60EA81B268C2560036E3944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2F626FE910DAC00A2F282560036EF829" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2F626FE910DAC00A2F282560036EF829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D361863A1144E1A1E8FB2560036E2981" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D361863A1144E1A1E8FB2560036E2981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_AF1C9760B142DBAABF572560036EDF90" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_326014524DB6ED8980002560036D7B84" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_AF1C9760B142DBAABF572560036EDF90" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_C2BF52C39CE822CA6F8CDDB186895FE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_E97C25CC44FF2C3B5083DDB18689D80E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C2BF52C39CE822CA6F8CDDB186895FE5" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_E97C25CC44FF2C3B5083DDB18689D80E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C25AFEBC5E87107483DCDDB1855A6B80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_CB1F2F02458E0328CD80DDB1855A2445" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C25AFEBC5E87107483DCDDB1855A6B80" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_CB1F2F02458E0328CD80DDB1855A2445" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C0CAE238C2B0140B1D36DDD3F71397FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8A8FD6D69EB17DA5A96ADDD3F713F546" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C0CAE238C2B0140B1D36DDD3F71397FD" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8A8FD6D69EB17DA5A96ADDD3F713F546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_99D41D6E44302B6CA46CDDD3F7136937" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8A8FD6D69EB17DA5A96ADDD3F713F546" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_99D41D6E44302B6CA46CDDD3F7136937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1DFF152E394B171470CCDDD3F713B46E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_99D41D6E44302B6CA46CDDD3F7136937" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1DFF152E394B171470CCDDD3F713B46E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_08AC187B133A30D051D5DDD3F714B590" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1DFF152E394B171470CCDDD3F713B46E" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_08AC187B133A30D051D5DDD3F714B590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3CC8DE913AEA034517C5DDD3F7141DFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8A8FD6D69EB17DA5A96ADDD3F713F546" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3CC8DE913AEA034517C5DDD3F7141DFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_37EC9D0121658F4AB1D8DDD3F714E74E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3CC8DE913AEA034517C5DDD3F7141DFF" xlink:to="loc_us-gaap_EquityComponentDomain_37EC9D0121658F4AB1D8DDD3F714E74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5C93F8F5A8ADE0DC5CD5DDD3F7149CE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_37EC9D0121658F4AB1D8DDD3F714E74E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5C93F8F5A8ADE0DC5CD5DDD3F7149CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DD3D2EAE2F5FC80B263EDDD3F715E9F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8A8FD6D69EB17DA5A96ADDD3F713F546" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DD3D2EAE2F5FC80B263EDDD3F715E9F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociTaxAttributableToParent" xlink:label="loc_us-gaap_AociTaxAttributableToParent_83F26ACD085607375A0CDDD3F715D9E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DD3D2EAE2F5FC80B263EDDD3F715E9F7" xlink:to="loc_us-gaap_AociTaxAttributableToParent_83F26ACD085607375A0CDDD3F715D9E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6908DF1AAC63EEEEB85DDDD3F715FE5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DD3D2EAE2F5FC80B263EDDD3F715E9F7" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6908DF1AAC63EEEEB85DDDD3F715FE5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_03179D885DF40F4693EC256002BCF3EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DEDC1282007CF9679AA6256002BCA6B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_03179D885DF40F4693EC256002BCF3EE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DEDC1282007CF9679AA6256002BCA6B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CFBAA0AE4D0759AB3FFE256002BC452E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_03179D885DF40F4693EC256002BCF3EE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_CFBAA0AE4D0759AB3FFE256002BC452E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FDCF4BB53AA9A52AD122256002BC109F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_03179D885DF40F4693EC256002BCF3EE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FDCF4BB53AA9A52AD122256002BC109F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_345FB3299E4DF2F95D14DDB186982779" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3FD549E0F2A70B9F096EDDB186983D4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_345FB3299E4DF2F95D14DDB186982779" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3FD549E0F2A70B9F096EDDB186983D4D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_944869D0FADEAF466190DDB1865D9962" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_F1AF21D9B2E4CE7D0050DDB1865DFB9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_944869D0FADEAF466190DDB1865D9962" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_F1AF21D9B2E4CE7D0050DDB1865DFB9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89CD48B530DD45C30EE1DDB185DD71CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_A40F572397D159F16C6EDDB185DD1B20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89CD48B530DD45C30EE1DDB185DD71CF" xlink:to="loc_us-gaap_NumberOfOperatingSegments_A40F572397D159F16C6EDDB185DD1B20" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D1AFAEB707ACDAB0C87DDB185B82072" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8145A3A7AB6D95D02E4DDB185B81F82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D1AFAEB707ACDAB0C87DDB185B82072" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8145A3A7AB6D95D02E4DDB185B81F82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C860FECBCA66148A2A2D434FF1DC7011" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_E2F27A97E5B20622EDF8434FF1DDE08D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C860FECBCA66148A2A2D434FF1DC7011" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_E2F27A97E5B20622EDF8434FF1DDE08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_BF8FFFF5B75DB0F511CF434FF1DD8953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_E2F27A97E5B20622EDF8434FF1DDE08D" xlink:to="loc_srt_RangeAxis_BF8FFFF5B75DB0F511CF434FF1DD8953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_AEE657D61601044A6B71434FF1DD641A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_BF8FFFF5B75DB0F511CF434FF1DD8953" xlink:to="loc_srt_RangeMember_AEE657D61601044A6B71434FF1DD641A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_916939F9D1550B7C0906434FF1DE5E52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_AEE657D61601044A6B71434FF1DD641A" xlink:to="loc_srt_MaximumMember_916939F9D1550B7C0906434FF1DE5E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_98DEAF38DD76D081A0D2434FF1DE3E47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_E2F27A97E5B20622EDF8434FF1DDE08D" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_98DEAF38DD76D081A0D2434FF1DE3E47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E3652A03B0B52E4F4F8F434FF1DEB17E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_98DEAF38DD76D081A0D2434FF1DE3E47" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E3652A03B0B52E4F4F8F434FF1DEB17E" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_RegulatoryApprovalMilestoneMember" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_ADDAAFC62E8881E7FB86434FF1DEC029" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E3652A03B0B52E4F4F8F434FF1DEB17E" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_ADDAAFC62E8881E7FB86434FF1DEC029" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:label="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_5D80B4DF3A88336C177E434FF1DEF32A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E3652A03B0B52E4F4F8F434FF1DEB17E" xlink:to="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_5D80B4DF3A88336C177E434FF1DEF32A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_D7C5048561B9139E9C06434FF1DF8005" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_E3652A03B0B52E4F4F8F434FF1DEB17E" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_D7C5048561B9139E9C06434FF1DF8005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_847A7EDAC0271EFFA91A434FF1DFAF0D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_E2F27A97E5B20622EDF8434FF1DDE08D" xlink:to="loc_srt_ProductOrServiceAxis_847A7EDAC0271EFFA91A434FF1DFAF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A4A9EC4AE245B3AFFAF4434FF1DFF51B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_847A7EDAC0271EFFA91A434FF1DFAF0D" xlink:to="loc_srt_ProductsAndServicesDomain_A4A9EC4AE245B3AFFAF4434FF1DFF51B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CftrActivatorsAndInhibitorsMember" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsMember_3E1F782E2BA8AD77EE28434FF1DFE95B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A4A9EC4AE245B3AFFAF4434FF1DFF51B" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsMember_3E1F782E2BA8AD77EE28434FF1DFE95B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_0297F9155B0142A46614434FF1DF7126" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_E2F27A97E5B20622EDF8434FF1DDE08D" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_0297F9155B0142A46614434FF1DF7126" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_8C59536A0206E12E2E97434FF1E0C248" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_0297F9155B0142A46614434FF1DF7126" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_8C59536A0206E12E2E97434FF1E0C248" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CftrActivatorsAndInhibitorsAbstract" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsAbstract_42AF953E2F5ADA0361EF434FF1E09E97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_0297F9155B0142A46614434FF1DF7126" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsAbstract_42AF953E2F5ADA0361EF434FF1E09E97" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_UpfrontLicenseFeeAndMilestonePaymentsMade" xlink:label="loc_vnda_UpfrontLicenseFeeAndMilestonePaymentsMade_AED1F7932E3AAB2CAFE6434FF1E0D481" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_42AF953E2F5ADA0361EF434FF1E09E97" xlink:to="loc_vnda_UpfrontLicenseFeeAndMilestonePaymentsMade_AED1F7932E3AAB2CAFE6434FF1E0D481" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_68D87173D50A43AD4EAC434FF1E02D43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_42AF953E2F5ADA0361EF434FF1E09E97" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_68D87173D50A43AD4EAC434FF1E02D43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56D0B9A90C2FD878DB03434FC4C23725" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_AB56B75CCB90B61DDC1F434FC4C513ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56D0B9A90C2FD878DB03434FC4C23725" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_AB56B75CCB90B61DDC1F434FC4C513ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_32D88716ED0FB0ED3B7D434FC4C69C3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_AB56B75CCB90B61DDC1F434FC4C513ED" xlink:to="loc_srt_ProductOrServiceAxis_32D88716ED0FB0ED3B7D434FC4C69C3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_001CFA772D6070969F70434FC4C66D0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_32D88716ED0FB0ED3B7D434FC4C69C3E" xlink:to="loc_srt_ProductsAndServicesDomain_001CFA772D6070969F70434FC4C66D0E" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_3001C9A8A733AFAEB350434FC4C77C69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_001CFA772D6070969F70434FC4C66D0E" xlink:to="loc_vnda_FanaptMember_3001C9A8A733AFAEB350434FC4C77C69" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_StatementScenarioSecondaryAxis" xlink:label="loc_vnda_StatementScenarioSecondaryAxis_F9AB6D4E6E2BDF0ED6AF434FC4C73E9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_AB56B75CCB90B61DDC1F434FC4C513ED" xlink:to="loc_vnda_StatementScenarioSecondaryAxis_F9AB6D4E6E2BDF0ED6AF434FC4C73E9E" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_StatementScenarioSecondaryDomain" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_9BDB2A511CE263FB48DE434FC4C72A0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_F9AB6D4E6E2BDF0ED6AF434FC4C73E9E" xlink:to="loc_vnda_StatementScenarioSecondaryDomain_9BDB2A511CE263FB48DE434FC4C72A0F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ScenarioFourMember" xlink:label="loc_vnda_ScenarioFourMember_2AD519A614EB0AE5ECF3434FC4C85EC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_StatementScenarioSecondaryDomain_9BDB2A511CE263FB48DE434FC4C72A0F" xlink:to="loc_vnda_ScenarioFourMember_2AD519A614EB0AE5ECF3434FC4C85EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E83FBF39FF3A96AB04A8434FC4C8CAC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_AB56B75CCB90B61DDC1F434FC4C513ED" xlink:to="loc_srt_RangeAxis_E83FBF39FF3A96AB04A8434FC4C8CAC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FB54873DE41DEEA41F5C434FC4C96D6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E83FBF39FF3A96AB04A8434FC4C8CAC3" xlink:to="loc_srt_RangeMember_FB54873DE41DEEA41F5C434FC4C96D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E490A2E6C45B856E8AA7434FC4C9F233" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FB54873DE41DEEA41F5C434FC4C96D6B" xlink:to="loc_srt_MaximumMember_E490A2E6C45B856E8AA7434FC4C9F233" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_4F3E15E8896E8F4CBFEB434FC4C91B70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_AB56B75CCB90B61DDC1F434FC4C513ED" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_4F3E15E8896E8F4CBFEB434FC4C91B70" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FanaptAbstract" xlink:label="loc_vnda_FanaptAbstract_0536CDAFE92FF04344B1434FC4C97731" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_4F3E15E8896E8F4CBFEB434FC4C91B70" xlink:to="loc_vnda_FanaptAbstract_0536CDAFE92FF04344B1434FC4C97731" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_RoyaltyPayableOnNetSalesPercentage" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_E97112EF37718A4FA21B434FC4CA36E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_FanaptAbstract_0536CDAFE92FF04344B1434FC4C97731" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_E97112EF37718A4FA21B434FC4CA36E5" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_RoyaltyPeriod" xlink:label="loc_vnda_RoyaltyPeriod_D3586B17245071F77A58434FC4CA6470" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_FanaptAbstract_0536CDAFE92FF04344B1434FC4C97731" xlink:to="loc_vnda_RoyaltyPeriod_D3586B17245071F77A58434FC4CA6470" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D056852968B4EF1E6E78DDD3F7501A98" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_37C1BA57A4756679F10ADDD3F75080B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D056852968B4EF1E6E78DDD3F7501A98" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_37C1BA57A4756679F10ADDD3F75080B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_900573537A42284DA71FDDD3F75060D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_37C1BA57A4756679F10ADDD3F75080B6" xlink:to="loc_srt_ProductOrServiceAxis_900573537A42284DA71FDDD3F75060D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0BBC2E52F3285D2C4EFBDDD3F751FDDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_900573537A42284DA71FDDD3F75060D3" xlink:to="loc_srt_ProductsAndServicesDomain_0BBC2E52F3285D2C4EFBDDD3F751FDDE" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_D22CC1769EC5DDB16F46DDD3F75160BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0BBC2E52F3285D2C4EFBDDD3F751FDDE" xlink:to="loc_vnda_HetliozMember_D22CC1769EC5DDB16F46DDD3F75160BB" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_E804FD380E5321810E9CDDD3F7513DAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_37C1BA57A4756679F10ADDD3F75080B6" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_E804FD380E5321810E9CDDD3F7513DAE" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_HetliozAbstract" xlink:label="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_E804FD380E5321810E9CDDD3F7513DAE" xlink:to="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_404A061EED9EB99ABD19DDD3F7520073" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_404A061EED9EB99ABD19DDD3F7520073" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CumulativeNetSalesToAchieveMilestone" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone_9962C5E4F70051C30357DDD3F752EDDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:to="loc_vnda_CumulativeNetSalesToAchieveMilestone_9962C5E4F70051C30357DDD3F752EDDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_E82D1349DAEE85CD1E41DDD3F752B859" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_E82D1349DAEE85CD1E41DDD3F752B859" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_RoyaltyPayableOnNetSalesPercentage" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_12A6D3C68A28D2030003DDD3F75233B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_12A6D3C68A28D2030003DDD3F75233B2" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_PercentageOfFutureSublicenseFeesPayable" xlink:label="loc_vnda_PercentageOfFutureSublicenseFeesPayable_6E6B1E8B2361EDD619D6DDD3F75282A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:to="loc_vnda_PercentageOfFutureSublicenseFeesPayable_6E6B1E8B2361EDD619D6DDD3F75282A5" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_RoyaltyPeriod" xlink:label="loc_vnda_RoyaltyPeriod_D74D39E017468B9B4FCFDDD3F75332C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_7B208C662B0994176514DDD3F7512D08" xlink:to="loc_vnda_RoyaltyPeriod_D74D39E017468B9B4FCFDDD3F75332C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesResearchAndDevelopmentAndMarketingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C21F132287E04C865E3FDDB1867CBDF7" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:label="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_937DE8DDFCD143981472DDB1867C6704" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C21F132287E04C865E3FDDB1867CBDF7" xlink:to="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_937DE8DDFCD143981472DDB1867C6704" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesSummaryOfNoncanellableLongTermContractualCashObligationsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CBAE4F2DA77B49AD30C3DDB185EA12CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CBAE4F2DA77B49AD30C3DDB185EA12CB" xlink:to="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_B154E7420C8A463513FBDDB185EB68FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:to="loc_us-gaap_PurchaseObligation_B154E7420C8A463513FBDDB185EB68FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_F3ECBD11820B238AA819DDB185EB2352" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_F3ECBD11820B238AA819DDB185EB2352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_BBF7BD8AD25752601C9ADDB185EC7C42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_BBF7BD8AD25752601C9ADDB185EC7C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_4D6435C557FD395273FCDDB185EC7FB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_4D6435C557FD395273FCDDB185EC7FB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_90FFBC38D565B04DC7E3DDB185EC1D0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_90FFBC38D565B04DC7E3DDB185EC1D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_6B48888CB2B95AA4A20ADDB185ECBAE5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_6B48888CB2B95AA4A20ADDB185ECBAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_B6824E7FB520C3E96772DDB185EC95D5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_A89007D81388313964BDDDB185EBA709" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_B6824E7FB520C3E96772DDB185EC95D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AA316E1AE9B11C86D7EDDDB186B56202" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_66F4B65DF58019E1BC75DDB186B5CF3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AA316E1AE9B11C86D7EDDDB186B56202" xlink:to="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_66F4B65DF58019E1BC75DDB186B5CF3F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A3EB41F0158184C9C932434FE0494D02" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_C6F5F35F5E4B5B7DE0C4434FE04947B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A3EB41F0158184C9C932434FE0494D02" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_C6F5F35F5E4B5B7DE0C4434FE04947B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C878F88ACFA9740B7738434FE049E863" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_C6F5F35F5E4B5B7DE0C4434FE04947B2" xlink:to="loc_srt_StatementGeographicalAxis_C878F88ACFA9740B7738434FE049E863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7A20AF70796ED7BFB990434FE0490A50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_C878F88ACFA9740B7738434FE049E863" xlink:to="loc_srt_SegmentGeographicalDomain_7A20AF70796ED7BFB990434FE0490A50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_FE3A6FC8DF4E344EA22E434FE04AF677" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7A20AF70796ED7BFB990434FE0490A50" xlink:to="loc_country_US_FE3A6FC8DF4E344EA22E434FE04AF677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_EA90AA7FF4F2BC08F670434FE04A1460" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7A20AF70796ED7BFB990434FE0490A50" xlink:to="loc_srt_EuropeMember_EA90AA7FF4F2BC08F670434FE04A1460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5392A4E4ACF9FF9C1E31434FE04AE755" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_C6F5F35F5E4B5B7DE0C4434FE04947B2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5392A4E4ACF9FF9C1E31434FE04AE755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D040CC2B1CB26C92E54434FE04A9C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5392A4E4ACF9FF9C1E31434FE04AE755" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D040CC2B1CB26C92E54434FE04A9C4F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_TradipitantMember" xlink:label="loc_vnda_TradipitantMember_B72CFDE755C2F16A916E434FE04B4899" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D040CC2B1CB26C92E54434FE04A9C4F" xlink:to="loc_vnda_TradipitantMember_B72CFDE755C2F16A916E434FE04B4899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_748E6902626C72672B23434FE04B8E38" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_C6F5F35F5E4B5B7DE0C4434FE04947B2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_748E6902626C72672B23434FE04B8E38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_125DA4FEE117B9CD7840434FE04BB0E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_748E6902626C72672B23434FE04B8E38" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_125DA4FEE117B9CD7840434FE04BB0E1" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_DevelopmentAndMilestonePaymentsOfPhaseThreeStudyPotentiallyDueToThirdPartyMember" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsOfPhaseThreeStudyPotentiallyDueToThirdPartyMember_B7B127C5F08EC5D57E00434FE04B238C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_125DA4FEE117B9CD7840434FE04BB0E1" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsOfPhaseThreeStudyPotentiallyDueToThirdPartyMember_B7B127C5F08EC5D57E00434FE04B238C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_RegulatoryApprovalMilestoneMember" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_A3A397C8B88B2FC3E115434FE04C1EF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_125DA4FEE117B9CD7840434FE04BB0E1" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_A3A397C8B88B2FC3E115434FE04C1EF2" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_SalesMilestoneMember" xlink:label="loc_vnda_SalesMilestoneMember_3AAE0CC87825C58C265F434FE04CA57A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_125DA4FEE117B9CD7840434FE04BB0E1" xlink:to="loc_vnda_SalesMilestoneMember_3AAE0CC87825C58C265F434FE04CA57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_89B27729B4085019BFC1434FE04CF725" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_C6F5F35F5E4B5B7DE0C4434FE04947B2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_89B27729B4085019BFC1434FE04CF725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B4AE8558D0EFE05EF18D434FE04C897C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_89B27729B4085019BFC1434FE04CF725" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B4AE8558D0EFE05EF18D434FE04C897C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5DB4A1E991F21560F317434FE04DB922" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B4AE8558D0EFE05EF18D434FE04C897C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5DB4A1E991F21560F317434FE04DB922" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_DBD19F13E65EAC0823CA434FE04D6FB6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_C6F5F35F5E4B5B7DE0C4434FE04947B2" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_DBD19F13E65EAC0823CA434FE04D6FB6" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_5B25E64DFC76586F9242434FE04D375A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_DBD19F13E65EAC0823CA434FE04D6FB6" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_5B25E64DFC76586F9242434FE04D375A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_E446EF3F42DBF4DC0A55434FE04DB065" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_DBD19F13E65EAC0823CA434FE04D6FB6" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_E446EF3F42DBF4DC0A55434FE04DB065" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_MilestoneObligationUnderLicenseAgreementCurrent" xlink:label="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_0FBE881DE7A94ECC6885434FE04D293D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_DBD19F13E65EAC0823CA434FE04D6FB6" xlink:to="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_0FBE881DE7A94ECC6885434FE04D293D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14426B6D5C24BABB9C4ADDB186608F51" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_660E9EEF3DB560658025DDB186608C76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14426B6D5C24BABB9C4ADDB186608F51" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_660E9EEF3DB560658025DDB186608C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1C35B45E88A239C54B10DDB186614B16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_660E9EEF3DB560658025DDB186608C76" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1C35B45E88A239C54B10DDB186614B16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_61F7DE8DD0CBB67091E9DDB186611C25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1C35B45E88A239C54B10DDB186614B16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_61F7DE8DD0CBB67091E9DDB186611C25" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_VQW765Member" xlink:label="loc_vnda_VQW765Member_CD43EC84BA084EE82EB2DDB186612654" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_61F7DE8DD0CBB67091E9DDB186611C25" xlink:to="loc_vnda_VQW765Member_CD43EC84BA084EE82EB2DDB186612654" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_9B5919DE0F6CC2A883ADDDB18662DAEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_660E9EEF3DB560658025DDB186608C76" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_9B5919DE0F6CC2A883ADDDB18662DAEF" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_5FBFE23E5CD4EDE9DA54DDB1866200A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_9B5919DE0F6CC2A883ADDDB18662DAEF" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_5FBFE23E5CD4EDE9DA54DDB1866200A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7667E120C05259D506861AED1C8C8024" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7667E120C05259D506861AED1C8C8024" xlink:to="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6999174FF15604FEACF41AED1C8D0807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6999174FF15604FEACF41AED1C8D0807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_E139ED2E8756E5CC11CA1AED1C8D1C76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_E139ED2E8756E5CC11CA1AED1C8D1C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1D6517EB43540AD561E11AED1C8EDF66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1D6517EB43540AD561E11AED1C8EDF66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9AEF3427FA060BC722301AED1C8E536D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:to="loc_us-gaap_InventoryNet_9AEF3427FA060BC722301AED1C8E536D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2455ED31E995E15DF4F71AED1C8EE6D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2455ED31E995E15DF4F71AED1C8EE6D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_834BF761AED19B363CDD1AED1C8E66C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5368648252028973E0081AED1C8D7E46" xlink:to="loc_us-gaap_AssetsCurrent_834BF761AED19B363CDD1AED1C8E66C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4B5DBA88C22A63C890581AF308E29C40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4B5DBA88C22A63C890581AF308E29C40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_136E2ED467813A0189D91AED1C8E6168" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_136E2ED467813A0189D91AED1C8E6168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_D584C0E501E9BE41C16C1AED1C8E1036" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_D584C0E501E9BE41C16C1AED1C8E1036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_BDA5DBDADC239EAC823E1AED1C8E8135" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_BDA5DBDADC239EAC823E1AED1C8E8135" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_InventoryAndOtherNonCurrent" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_658E86E4853CD39867B31AED1C8F4A31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:to="loc_vnda_InventoryAndOtherNonCurrent_658E86E4853CD39867B31AED1C8F4A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_EF3B98314FB69765D3781AED1C8FFE34" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8B227E62DDAB02FB70FA1AED1C8D1252" xlink:to="loc_us-gaap_Assets_EF3B98314FB69765D3781AED1C8FFE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7667E120C05259D506861AED1C8C8024" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_A56FA8C051CF2F37C1671AED1C8F5860" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_A56FA8C051CF2F37C1671AED1C8F5860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_391889B15BCEABBCF0381AED1C8F370A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A56FA8C051CF2F37C1671AED1C8F5860" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_391889B15BCEABBCF0381AED1C8F370A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ProductRevenueAllowancesCurrent" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_D2CECA3A51F0D25323A51AED1C907D75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A56FA8C051CF2F37C1671AED1C8F5860" xlink:to="loc_vnda_ProductRevenueAllowancesCurrent_D2CECA3A51F0D25323A51AED1C907D75" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_MilestoneObligationUnderLicenseAgreementCurrent" xlink:label="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_6C67477F11AE89E8F2F81AED1C902E4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A56FA8C051CF2F37C1671AED1C8F5860" xlink:to="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_6C67477F11AE89E8F2F81AED1C902E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6415CD5D9199DB64FB4B1AED1C90F94E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A56FA8C051CF2F37C1671AED1C8F5860" xlink:to="loc_us-gaap_LiabilitiesCurrent_6415CD5D9199DB64FB4B1AED1C90F94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7241125C0AEF14E4C9B31AED1C90650B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7241125C0AEF14E4C9B31AED1C90650B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D3B54759593A9ADD416B1AED1C9007C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_D3B54759593A9ADD416B1AED1C9007C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_CCFB576574F68F62C79D1AED1C91E835" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:to="loc_us-gaap_Liabilities_CCFB576574F68F62C79D1AED1C91E835" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_66E581741E37F8371CD41AED1C917582" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:to="loc_us-gaap_CommitmentsAndContingencies_66E581741E37F8371CD41AED1C917582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:to="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B77D8F1ACDE636BF92221AED1C9196B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:to="loc_us-gaap_PreferredStockValue_B77D8F1ACDE636BF92221AED1C9196B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2202CCBEB624058780BA1AED1C913B87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:to="loc_us-gaap_CommonStockValue_2202CCBEB624058780BA1AED1C913B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_513AF56439DA786926331AED1C92A659" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_513AF56439DA786926331AED1C92A659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747F49A563B22CC2C5161AED1C9257D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747F49A563B22CC2C5161AED1C9257D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ECF9A01A63FE6B5ABB071AED1C92D730" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ECF9A01A63FE6B5ABB071AED1C92D730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_961CB6D8FB93583128251AED1C92697B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D594C15AF4D011136ECB1AED1C910A73" xlink:to="loc_us-gaap_StockholdersEquity_961CB6D8FB93583128251AED1C92697B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_F69C1F6257B347766A711AED1C92AA8A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DE6D0BF4F8C90019F3DB1AED1C8F801D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_F69C1F6257B347766A711AED1C92AA8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1E74E7E21C24E00B2AF7DDB1865A5EF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1E74E7E21C24E00B2AF7DDB1865A5EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C8EF198079E6804D616CDDB1865AEF7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_C8EF198079E6804D616CDDB1865AEF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6E289CB074981170ECE0DDB1865A4B8C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6E289CB074981170ECE0DDB1865A4B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_26E96E14CC2804A00F04DDB1865A2348" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_26E96E14CC2804A00F04DDB1865A2348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_91FACE1E2F20EC69DA2EDDB1865BCA9B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_91FACE1E2F20EC69DA2EDDB1865BCA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DE0F89422BF51EC01F19DDB1865BE313" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DE0F89422BF51EC01F19DDB1865BE313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F2AE4C3DC8343611234BDDB1865B9632" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_CommonStockSharesIssued_F2AE4C3DC8343611234BDDB1865B9632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F7103491F35746B10855DDB1865BD21C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_00340ACD936F47431851DDB18659C8C9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F7103491F35746B10855DDB1865BD21C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_129CCD4F7185003F94FA2560044CB8BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1DFBF4A4DC9373D0B8C92560044CA752" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_129CCD4F7185003F94FA2560044CB8BA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1DFBF4A4DC9373D0B8C92560044CA752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4578E515748124B3FAA12560044C3549" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1DFBF4A4DC9373D0B8C92560044CA752" xlink:to="loc_us-gaap_NetIncomeLoss_4578E515748124B3FAA12560044C3549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1DFBF4A4DC9373D0B8C92560044CA752" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_C2CC98455A9C62D2B45C2560044CCC93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:to="loc_us-gaap_Depreciation_C2CC98455A9C62D2B45C2560044CCC93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D8C7D5069C177B1BC1D02560044C97A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:to="loc_us-gaap_ShareBasedCompensation_D8C7D5069C177B1BC1D02560044C97A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_212D8C5658891F7FE07B2560044C6988" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_212D8C5658891F7FE07B2560044C6988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_55B1C377EF128E52D2202560044C7F38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_55B1C377EF128E52D2202560044C7F38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3D30CB3E2939BF256A612560044C6B77" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3D30CB3E2939BF256A612560044C6B77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EF2241AF5AFA1C7570B42560044C2FCF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EFCA574458BE22D7F1C42560044CD882" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EF2241AF5AFA1C7570B42560044C2FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7EEBFC883500D4B68D292560044CE4E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EF2241AF5AFA1C7570B42560044C2FCF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7EEBFC883500D4B68D292560044CE4E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65E3968D74A47FEE18F52560044C79CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EF2241AF5AFA1C7570B42560044C2FCF" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65E3968D74A47FEE18F52560044C79CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_CB15A026ADE98A0291ED2560044C4E46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EF2241AF5AFA1C7570B42560044C2FCF" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_CB15A026ADE98A0291ED2560044C4E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_FA2FC2875FB63113D9002560044CDC31" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EF2241AF5AFA1C7570B42560044C2FCF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_FA2FC2875FB63113D9002560044CDC31" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_IncreaseDecreaseProductRevenueAllowances" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_B72A9324CF4F66C25C6E2560044C7A13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_EF2241AF5AFA1C7570B42560044C2FCF" xlink:to="loc_vnda_IncreaseDecreaseProductRevenueAllowances_B72A9324CF4F66C25C6E2560044C7A13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4E3091B1F3309F8236152560044C96EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1DFBF4A4DC9373D0B8C92560044CA752" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4E3091B1F3309F8236152560044C96EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9D736ED772AAE3C586772560044C4187" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_129CCD4F7185003F94FA2560044CB8BA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9D736ED772AAE3C586772560044C4187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_B99F1A37E67FA3BB6AA72560044C54F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9D736ED772AAE3C586772560044C4187" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_B99F1A37E67FA3BB6AA72560044C54F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E93F91D3D064DAB0EDE92560044CA67A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9D736ED772AAE3C586772560044C4187" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E93F91D3D064DAB0EDE92560044CA67A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_88023331DADB6AE853D12560044CF46D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9D736ED772AAE3C586772560044C4187" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_88023331DADB6AE853D12560044CF46D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_179C7AD88625EDB6FFA12560044CA209" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9D736ED772AAE3C586772560044C4187" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_179C7AD88625EDB6FFA12560044CA209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_EDC51E76D39595CA465B2560044C15D3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9D736ED772AAE3C586772560044C4187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_EDC51E76D39595CA465B2560044C15D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B0212A8793481E79903F2560044C8BC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_129CCD4F7185003F94FA2560044CB8BA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B0212A8793481E79903F2560044C8BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5346943A310D1526A2952560044CF8D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B0212A8793481E79903F2560044C8BC2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5346943A310D1526A2952560044CF8D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_C74615D737E5B7FF9CF32560044C4A61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B0212A8793481E79903F2560044C8BC2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_C74615D737E5B7FF9CF32560044C4A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_B5D16E6AE0510640CDFB2560044CDFB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B0212A8793481E79903F2560044C8BC2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_B5D16E6AE0510640CDFB2560044CDFB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FF1140445B49801C99062560044C84D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_129CCD4F7185003F94FA2560044CB8BA" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FF1140445B49801C99062560044C84D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3F3F38FCD5358C1D39212560044C36C3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_129CCD4F7185003F94FA2560044CB8BA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3F3F38FCD5358C1D39212560044C36C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9A5CE905E96A4F7C2F7C2560044C720F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_129CCD4F7185003F94FA2560044CB8BA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9A5CE905E96A4F7C2F7C2560044C720F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51F8D3C58BE0D41D1B862560044C43AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9A5CE905E96A4F7C2F7C2560044C720F" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51F8D3C58BE0D41D1B862560044C43AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3CB295A44EE6D55BE76C2560044CE2BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9A5CE905E96A4F7C2F7C2560044C720F" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3CB295A44EE6D55BE76C2560044CE2BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_FBB5F70A3C3E06A2C9933FB7DF0AE3E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_207C0E6C325018A48FB03FB7DF0BB700" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_FBB5F70A3C3E06A2C9933FB7DF0AE3E9" xlink:to="loc_us-gaap_StatementTable_207C0E6C325018A48FB03FB7DF0BB700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BD857BBEE88BFE8EFDF83FB7DF0B354D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_207C0E6C325018A48FB03FB7DF0BB700" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BD857BBEE88BFE8EFDF83FB7DF0B354D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E79613745597FAADF8023FB7DF0BE04A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BD857BBEE88BFE8EFDF83FB7DF0B354D" xlink:to="loc_us-gaap_EquityComponentDomain_E79613745597FAADF8023FB7DF0BE04A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B49996BCDCD0A70D3DAE3FB7DF0C4561" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E79613745597FAADF8023FB7DF0BE04A" xlink:to="loc_us-gaap_CommonStockMember_B49996BCDCD0A70D3DAE3FB7DF0C4561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_066D200019103956CFB13FB7DF0C5DFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E79613745597FAADF8023FB7DF0BE04A" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_066D200019103956CFB13FB7DF0C5DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FFBADA2F8591B3A8B363FB7DF0C064D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E79613745597FAADF8023FB7DF0BE04A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FFBADA2F8591B3A8B363FB7DF0C064D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1C9D330BFD81FF691EB93FB7DF0CD269" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E79613745597FAADF8023FB7DF0BE04A" xlink:to="loc_us-gaap_RetainedEarningsMember_1C9D330BFD81FF691EB93FB7DF0CD269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AB76CC021AF23FA985663FB7DF0C1F63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_207C0E6C325018A48FB03FB7DF0BB700" xlink:to="loc_us-gaap_StatementLineItems_AB76CC021AF23FA985663FB7DF0C1F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AB76CC021AF23FA985663FB7DF0C1F63" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_73BAA7B704D45C6DCCAE3FB7DF0D2E91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_73BAA7B704D45C6DCCAE3FB7DF0D2E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2381EF1E40C998D178093FB7DF0DB62D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_StockholdersEquity_2381EF1E40C998D178093FB7DF0DB62D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F880CC3D8B743A154CDE3FB7DF0D9FD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F880CC3D8B743A154CDE3FB7DF0D9FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8808279C3412C5630D8F3FB7DF0D686D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8808279C3412C5630D8F3FB7DF0D686D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3D2FF584BFBFD94BFF5E3FB7DF0D6FF7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3D2FF584BFBFD94BFF5E3FB7DF0D6FF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8F71DD802066618A77073FB7DF0E5C24" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8F71DD802066618A77073FB7DF0E5C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33D1441A8A1F7DDA159E3FB7DF0E0F78" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33D1441A8A1F7DDA159E3FB7DF0E0F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_51074B42FD0ED1787F6F3FB7DF0E0AD6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_NetIncomeLoss_51074B42FD0ED1787F6F3FB7DF0E0AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E3D542D5EB1A608B098D3FB7DF0E6F15" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E3D542D5EB1A608B098D3FB7DF0E6F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3B12C157AB9A848C9C123FB7DF0E81BB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3B12C157AB9A848C9C123FB7DF0E81BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1F77E94C9D6104BC19A13FB7DF0E4D1E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9FF0C9C45F4B476275EF3FB7DF0CB1B6" xlink:to="loc_us-gaap_StockholdersEquity_1F77E94C9D6104BC19A13FB7DF0E4D1E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_448EFC7ECD96F3BFA6191AED1C72D3FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_964A65D765FFEE5FB9301AED1C72EF64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_448EFC7ECD96F3BFA6191AED1C72D3FC" xlink:to="loc_us-gaap_NetIncomeLoss_964A65D765FFEE5FB9301AED1C72EF64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_A0CFA557CAD9654903871AED1C722ED9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_448EFC7ECD96F3BFA6191AED1C72D3FC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_A0CFA557CAD9654903871AED1C722ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1627748278E0472184441AED1C72527A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_A0CFA557CAD9654903871AED1C722ED9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1627748278E0472184441AED1C72527A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_6D4279B344B9B93F2E711AED1C733C49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_A0CFA557CAD9654903871AED1C722ED9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_6D4279B344B9B93F2E711AED1C733C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_0CCB8A31E145E426FE121AED1C739204" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_A0CFA557CAD9654903871AED1C722ED9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_0CCB8A31E145E426FE121AED1C739204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2E5FD8D21C15557AAAE71AED1C73C2AF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_A0CFA557CAD9654903871AED1C722ED9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2E5FD8D21C15557AAAE71AED1C73C2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4E04E9DBC72638736FA81AED1C73DFC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_448EFC7ECD96F3BFA6191AED1C72D3FC" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4E04E9DBC72638736FA81AED1C73DFC5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0D193F492A2A11D27A4F1AED1C793B7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_RevenuesAbstract_0D193F492A2A11D27A4F1AED1C793B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7A44F7DF30609A8BF15F1AED1C7A845C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0D193F492A2A11D27A4F1AED1C793B7D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7A44F7DF30609A8BF15F1AED1C7A845C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_6440D25FEBAE57207ED71AED1C7A17B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0D193F492A2A11D27A4F1AED1C793B7D" xlink:to="loc_us-gaap_Revenues_6440D25FEBAE57207ED71AED1C7A17B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2C5BDBB3CC0E48A124231AED1C7A7EB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2C5BDBB3CC0E48A124231AED1C7A7EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization_66FECB6F3903AF0CD1EE1AED1C7ACD87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2C5BDBB3CC0E48A124231AED1C7A7EB6" xlink:to="loc_us-gaap_CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization_66FECB6F3903AF0CD1EE1AED1C7ACD87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_92CE3B53A0F184955BFE1AED1C7B8249" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2C5BDBB3CC0E48A124231AED1C7A7EB6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_92CE3B53A0F184955BFE1AED1C7B8249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2AFF43F720FECA1C1EF41AED1C7B8159" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2C5BDBB3CC0E48A124231AED1C7A7EB6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2AFF43F720FECA1C1EF41AED1C7B8159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5EC88AD5D95F2FB8A9921AED1C7B07C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2C5BDBB3CC0E48A124231AED1C7A7EB6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5EC88AD5D95F2FB8A9921AED1C7B07C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_11468FF40228CAB4820D1AED1C7B9050" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2C5BDBB3CC0E48A124231AED1C7A7EB6" xlink:to="loc_us-gaap_CostsAndExpenses_11468FF40228CAB4820D1AED1C7B9050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FA7AF07CDCE338B040AB1AED1C7B9465" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_OperatingIncomeLoss_FA7AF07CDCE338B040AB1AED1C7B9465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_A3618352F1E9441AA6D91AED1C7C05E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_OtherIncome_A3618352F1E9441AA6D91AED1C7C05E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3379A3A0320E306601101AED1C7C73B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3379A3A0320E306601101AED1C7C73B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A55A12E15E3A920D16D31AED1C7CA468" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A55A12E15E3A920D16D31AED1C7CA468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B18235A37BC27A0CD9441AED1C7CE1D5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_NetIncomeLoss_B18235A37BC27A0CD9441AED1C7CE1D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_FE202D111890A847D3F71AED1C7CA5D5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_EarningsPerShareAbstract_FE202D111890A847D3F71AED1C7CA5D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F4F7702C930E918B96451AED1C7C7623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FE202D111890A847D3F71AED1C7CA5D5" xlink:to="loc_us-gaap_EarningsPerShareBasic_F4F7702C930E918B96451AED1C7C7623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7DB68E6E48F3A6B10E7F1AED1C7D7C9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FE202D111890A847D3F71AED1C7CA5D5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7DB68E6E48F3A6B10E7F1AED1C7D7C9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_F638D62DC4949146582B1AED1C7D5CD2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5BFCB8483FF64327EC421AED1C790425" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_F638D62DC4949146582B1AED1C7D5CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C8241C5FD41222F27FDA1AED1C7D85DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_F638D62DC4949146582B1AED1C7D5CD2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C8241C5FD41222F27FDA1AED1C7D85DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E5B3F0FC22A6AFBEE6F21AED1C7D2885" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_F638D62DC4949146582B1AED1C7D5CD2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E5B3F0FC22A6AFBEE6F21AED1C7D2885" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8B98770826153FBC2A9848863F3915D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_DocumentType_8B98770826153FBC2A9848863F3915D2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8A94EA6A52EFED236F3148863F39B99E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_AmendmentFlag_8A94EA6A52EFED236F3148863F39B99E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_FE0839E4299D78D8855448863F390CAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_DocumentQuarterlyReport_FE0839E4299D78D8855448863F390CAC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_FC6A1B0E574C606BD13948863F396041" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_DocumentPeriodEndDate_FC6A1B0E574C606BD13948863F396041" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_83476BE50B37C47E47B548863F39E445" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_DocumentFiscalPeriodFocus_83476BE50B37C47E47B548863F39E445" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_78A5A9F9052F7316FCE048863F3A6516" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_CurrentFiscalYearEndDate_78A5A9F9052F7316FCE048863F3A6516" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C753F3053A26262179FA48863F3A86F7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_DocumentFiscalYearFocus_C753F3053A26262179FA48863F3A86F7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_CA0BB6E2F6839A641E1848863F3A931E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_DocumentTransitionReport_CA0BB6E2F6839A641E1848863F3A931E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_E9BEC4DC47F8C5641A4D48863F3A8C1C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityFileNumber_E9BEC4DC47F8C5641A4D48863F3A8C1C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3A2EE5E19E81C8BB11FC48863F3A610F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityRegistrantName_3A2EE5E19E81C8BB11FC48863F3A610F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1EE6EA06029ACDBCCC6C48863F3BE8BE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityCentralIndexKey_1EE6EA06029ACDBCCC6C48863F3BE8BE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_28B6DCC8C8372A53494348863F3BC9DF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityIncorporationStateCountryCode_28B6DCC8C8372A53494348863F3BC9DF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_3BA7EB85A9B33A7A1FBE48863F3B87DA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityTaxIdentificationNumber_3BA7EB85A9B33A7A1FBE48863F3B87DA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_60AF55B49F8A352F835748863F3B1844" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityAddressAddressLine1_60AF55B49F8A352F835748863F3B1844" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_A5C5451812BD0A360DEA48863F3B8D59" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityAddressPostalZipCode_A5C5451812BD0A360DEA48863F3B8D59" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_E2C0327740B81C10B1E748863F3BE14C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityAddressAddressLine2_E2C0327740B81C10B1E748863F3BE14C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_6EDE89CB5654C3DA651E48863F3C5899" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityAddressCityOrTown_6EDE89CB5654C3DA651E48863F3C5899" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_A9293A9D85556D191DED48863F3CFE36" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityAddressStateOrProvince_A9293A9D85556D191DED48863F3CFE36" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_BE70C6528994E4D7C3C348863F3C1B8D" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_CityAreaCode_BE70C6528994E4D7C3C348863F3C1B8D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_98B5E4A184F33D3EDE3348863F3C3D7D" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_LocalPhoneNumber_98B5E4A184F33D3EDE3348863F3C3D7D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_BB3621B29D1FF31960A248863F3C7812" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_Security12bTitle_BB3621B29D1FF31960A248863F3C7812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2ED70E875411A767EC5648863F3CDDDD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2ED70E875411A767EC5648863F3CDDDD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_A33A7112C43B1F21096748863F3CE7D7" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_TradingSymbol_A33A7112C43B1F21096748863F3CE7D7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_C6E553C365933EED088948863F3D0B9F" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_SecurityExchangeName_C6E553C365933EED088948863F3D0B9F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_7CAA6F5BE3BC8FEC12AD48863F3D48F4" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityCurrentReportingStatus_7CAA6F5BE3BC8FEC12AD48863F3D48F4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_7D6A6210CDB90C887D1C48863F3DFEB6" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityInteractiveDataCurrent_7D6A6210CDB90C887D1C48863F3DFEB6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6CF11D559CE6B6ED2C2F48863F3DFD43" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityFilerCategory_6CF11D559CE6B6ED2C2F48863F3DFD43" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_53C6764B1EFD633E7B3148863F3D1691" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntitySmallBusiness_53C6764B1EFD633E7B3148863F3D1691" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8DD40EA7EA6ECBC4E02548863F3D21C4" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityEmergingGrowthCompany_8DD40EA7EA6ECBC4E02548863F3D21C4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_8874B31256322EA1D85248863F3E4A96" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityShellCompany_8874B31256322EA1D85248863F3E4A96" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D11FF4EF1A2C0A1FE80048863F3EFCFB" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_673C9FBB27E8744A46A048863F3836AC" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_D11FF4EF1A2C0A1FE80048863F3EFCFB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6A0254019E72F14F2893DDB1855C3E28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2C7BC3E0DB24649F997CDDB1855CE813" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6A0254019E72F14F2893DDB1855C3E28" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2C7BC3E0DB24649F997CDDB1855CE813" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_846D497784A51B737400DDD3F6C68268" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_2640DE5A6BB0BDA29603DDD3F6C60ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_846D497784A51B737400DDD3F6C68268" xlink:to="loc_us-gaap_NetIncomeLossAbstract_2640DE5A6BB0BDA29603DDD3F6C60ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_28D94EF64DA8EDBD8A29DDD3F6C6E83B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_2640DE5A6BB0BDA29603DDD3F6C60ABC" xlink:to="loc_us-gaap_NetIncomeLoss_28D94EF64DA8EDBD8A29DDD3F6C6E83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8BD039386CB0CD282DE6DDD3F6C71AF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_846D497784A51B737400DDD3F6C68268" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8BD039386CB0CD282DE6DDD3F6C71AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90C643BB640889D7B971DDD3F6C7DB6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8BD039386CB0CD282DE6DDD3F6C71AF4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90C643BB640889D7B971DDD3F6C7DB6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830D721A072345517451DDD3F6C70F9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8BD039386CB0CD282DE6DDD3F6C71AF4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830D721A072345517451DDD3F6C70F9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1CCA99BB787CB5F0E36EDDD3F6C75334" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_8BD039386CB0CD282DE6DDD3F6C71AF4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1CCA99BB787CB5F0E36EDDD3F6C75334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AACEE27E4BD1B9AADDD6DDD3F6C8CEE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_846D497784A51B737400DDD3F6C68268" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AACEE27E4BD1B9AADDD6DDD3F6C8CEE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_26C22135236252D5158EDDD3F6C86353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AACEE27E4BD1B9AADDD6DDD3F6C8CEE8" xlink:to="loc_us-gaap_EarningsPerShareBasic_26C22135236252D5158EDDD3F6C86353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_A0F30AB949036C1F1826DDD3F6C8BBDE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AACEE27E4BD1B9AADDD6DDD3F6C8CEE8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_A0F30AB949036C1F1826DDD3F6C8BBDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_FEE144CF509F9C2ADB1DDDD3F6C8FF1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AACEE27E4BD1B9AADDD6DDD3F6C8CEE8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_FEE144CF509F9C2ADB1DDDD3F6C8FF1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_090D948126466BBD699DDDB186CADBC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C79C79992AEB7DE2D885DDB186CA2BFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_090D948126466BBD699DDDB186CADBC1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C79C79992AEB7DE2D885DDB186CA2BFA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8C7D9C41D8483C972D16DDB18694DA49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_A25232FBB06561EFAC0CDDB1869498A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8C7D9C41D8483C972D16DDB18694DA49" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_A25232FBB06561EFAC0CDDB1869498A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CAFA44188A365C15D4DFDDB1856003CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E4D94DD0A6B62B2F2CE1DDB185610FEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CAFA44188A365C15D4DFDDB1856003CF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E4D94DD0A6B62B2F2CE1DDB185610FEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1951101643C0A22AF8EADDB185611BF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E4D94DD0A6B62B2F2CE1DDB185610FEF" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1951101643C0A22AF8EADDB185611BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1EECBA79A6767EE00912DDB18561A464" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1951101643C0A22AF8EADDB185611BF1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1EECBA79A6767EE00912DDB18561A464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3328C30DB88F9C13CEDFDDB18562E25F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1EECBA79A6767EE00912DDB18561A464" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3328C30DB88F9C13CEDFDDB18562E25F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_110BCE243E39E5F789BDDDB1856245E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1EECBA79A6767EE00912DDB18561A464" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_110BCE243E39E5F789BDDDB1856245E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_AB777797D80C51D48A25DDB18562D504" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1EECBA79A6767EE00912DDB18561A464" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_AB777797D80C51D48A25DDB18562D504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5C5A9ECA91A6FEA53783DDB18562D2CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E4D94DD0A6B62B2F2CE1DDB185610FEF" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5C5A9ECA91A6FEA53783DDB18562D2CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23FC98D7D021C81D52F6DDB18562F0F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5C5A9ECA91A6FEA53783DDB18562D2CD" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23FC98D7D021C81D52F6DDB18562F0F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_34CFA99353A0CCEB6D47DDB185632D7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23FC98D7D021C81D52F6DDB18562F0F9" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_34CFA99353A0CCEB6D47DDB185632D7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_61801CDCCBC5F2442E74DDB185630C45" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23FC98D7D021C81D52F6DDB18562F0F9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_61801CDCCBC5F2442E74DDB185630C45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_F77660944C1FBC09A8E6DDB1856367E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23FC98D7D021C81D52F6DDB18562F0F9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_F77660944C1FBC09A8E6DDB1856367E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EA3482C0FA18A30F3DE6DDB1856366A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E4D94DD0A6B62B2F2CE1DDB185610FEF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EA3482C0FA18A30F3DE6DDB1856366A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ACEC55389EEA287E08D3DDB18563474D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EA3482C0FA18A30F3DE6DDB1856366A8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ACEC55389EEA287E08D3DDB18563474D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_783CA05117628A9CA079DDB186B7FAFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6A9D17B52E0BC03B938ADDB186B7DD48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_783CA05117628A9CA079DDB186B7FAFC" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6A9D17B52E0BC03B938ADDB186B7DD48" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09A74DDF7510A34F368ADDB18601A47A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_DF282B4EF8F0423555C2DDB186015638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09A74DDF7510A34F368ADDB18601A47A" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_DF282B4EF8F0423555C2DDB186015638" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_166EAC52389EF7042F46461E6B3B9EB1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3FEA087682E3BB8E6929461E6B3B4B0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_166EAC52389EF7042F46461E6B3B9EB1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3FEA087682E3BB8E6929461E6B3B4B0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E4AC9CD0F4E0EBBADEDFDDB1860474D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_16EAE3A450F48A3F1A3DDDB1860468DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E4AC9CD0F4E0EBBADEDFDDB1860474D2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_16EAE3A450F48A3F1A3DDDB1860468DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_10C6641ABB095E6B74B6DDB1860571DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_16EAE3A450F48A3F1A3DDDB1860468DB" xlink:to="loc_srt_ProductOrServiceAxis_10C6641ABB095E6B74B6DDB1860571DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0CD125CA1291BA2CBBE6DDB186056B04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_10C6641ABB095E6B74B6DDB1860571DC" xlink:to="loc_srt_ProductsAndServicesDomain_0CD125CA1291BA2CBBE6DDB186056B04" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_807BD52C6982EDFB3141DDB186056476" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0CD125CA1291BA2CBBE6DDB186056B04" xlink:to="loc_vnda_FanaptMember_807BD52C6982EDFB3141DDB186056476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_440B05E3C867607485E7DDB18605B7F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_16EAE3A450F48A3F1A3DDDB1860468DB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_440B05E3C867607485E7DDB18605B7F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_407E17CBE81FAE251198DDB18606186D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_440B05E3C867607485E7DDB18605B7F4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_407E17CBE81FAE251198DDB18606186D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38EA26AE75E2A0CC133CDDB186669178" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_256AD884B29F595B399FDDB186664DD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38EA26AE75E2A0CC133CDDB186669178" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_256AD884B29F595B399FDDB186664DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_88286A1D067AB34FE8FEDDB186666742" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_256AD884B29F595B399FDDB186664DD0" xlink:to="loc_srt_ProductOrServiceAxis_88286A1D067AB34FE8FEDDB186666742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EEC1818BED85A13CF631DDB18666A275" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_88286A1D067AB34FE8FEDDB186666742" xlink:to="loc_srt_ProductsAndServicesDomain_EEC1818BED85A13CF631DDB18666A275" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_BE47FE3FF218A8EF7BA8DDB186679B43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EEC1818BED85A13CF631DDB18666A275" xlink:to="loc_vnda_HetliozMember_BE47FE3FF218A8EF7BA8DDB186679B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F4307192B2A3FA562558DDB18667B958" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_256AD884B29F595B399FDDB186664DD0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F4307192B2A3FA562558DDB18667B958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3AD76E7A593C6E160672DDB18667B45C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F4307192B2A3FA562558DDB18667B958" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3AD76E7A593C6E160672DDB18667B45C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CumulativeNetSalesToAchieveMilestone" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone_66EE71F817D5667D1B51DDB18668D092" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F4307192B2A3FA562558DDB18667B958" xlink:to="loc_vnda_CumulativeNetSalesToAchieveMilestone_66EE71F817D5667D1B51DDB18668D092" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_MilestoneObligationUnderLicenseAgreementCurrent" xlink:label="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_CDDA2120C0EE266AFA0EDDB18668CC5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F4307192B2A3FA562558DDB18667B958" xlink:to="loc_vnda_MilestoneObligationUnderLicenseAgreementCurrent_CDDA2120C0EE266AFA0EDDB18668CC5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_B64958D38AF2D268EB6FDDB18668CFF3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_F4307192B2A3FA562558DDB18667B958" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_B64958D38AF2D268EB6FDDB18668CFF3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D59B8207E2483D90BB0ADDB186222806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0B991F68BFFDD530D806DDB186237BE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D59B8207E2483D90BB0ADDB186222806" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0B991F68BFFDD530D806DDB186237BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9C0222C4D81984F24C24DDB18623A404" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0B991F68BFFDD530D806DDB186237BE0" xlink:to="loc_srt_ProductOrServiceAxis_9C0222C4D81984F24C24DDB18623A404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0459A6A4B6DB5E489CDDDDB1862359CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9C0222C4D81984F24C24DDB18623A404" xlink:to="loc_srt_ProductsAndServicesDomain_0459A6A4B6DB5E489CDDDDB1862359CA" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_87F486B604B44371001CDDB18623706E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0459A6A4B6DB5E489CDDDDB1862359CA" xlink:to="loc_vnda_HetliozMember_87F486B604B44371001CDDB18623706E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0B991F68BFFDD530D806DDB186237BE0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7BA62B2DD8E5DD92F340DDB1862489BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7BA62B2DD8E5DD92F340DDB1862489BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7379C60C88266E20E713DDB186241721" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7379C60C88266E20E713DDB186241721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1E254E39C135089D0924DDB18624B5F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1E254E39C135089D0924DDB18624B5F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_550EAA45D67BA112E629DDB1862582D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_550EAA45D67BA112E629DDB1862582D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6D5680C3EECD5C4E2D85DDB186252E0E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6D5680C3EECD5C4E2D85DDB186252E0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5A8033139FD2897C7250DDB1862589D0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5A8033139FD2897C7250DDB1862589D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_D09E05C4581DA2B681D3DDB18625F870" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_02668DA4C0EDE92C59F1DDB18624B70B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_D09E05C4581DA2B681D3DDB18625F870" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_12E15F887343BB76E915DDB18680C531" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_DA5F3AD4D84EBACCFE65DDB186808B87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_12E15F887343BB76E915DDB18680C531" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_DA5F3AD4D84EBACCFE65DDB186808B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EB42A5DC7A837B41819DDDB18680A92B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_DA5F3AD4D84EBACCFE65DDB186808B87" xlink:to="loc_srt_ProductOrServiceAxis_EB42A5DC7A837B41819DDDB18680A92B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_FD11E25BA0F3DE74B622DDB1868099DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_EB42A5DC7A837B41819DDDB18680A92B" xlink:to="loc_srt_ProductsAndServicesDomain_FD11E25BA0F3DE74B622DDB1868099DC" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_F8E945DAF257B6F99586DDB1868192E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_FD11E25BA0F3DE74B622DDB1868099DC" xlink:to="loc_vnda_HetliozMember_F8E945DAF257B6F99586DDB1868192E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62D658D281760799C640DDB18681FD6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_DA5F3AD4D84EBACCFE65DDB186808B87" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62D658D281760799C640DDB18681FD6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2B4DD73398CA7354B2BBDDB186812BA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62D658D281760799C640DDB18681FD6E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2B4DD73398CA7354B2BBDDB186812BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7802DE1C5698DA15FE75DDB1868107F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62D658D281760799C640DDB18681FD6E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7802DE1C5698DA15FE75DDB1868107F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9BBCCA847A1C960C164EDDB186824EC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62D658D281760799C640DDB18681FD6E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9BBCCA847A1C960C164EDDB186824EC7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0999DCE1B7B6B1991C7BDDB185E09A83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_83DF2E9E6AD51C26EDC9DDB185E04E6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0999DCE1B7B6B1991C7BDDB185E09A83" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_83DF2E9E6AD51C26EDC9DDB185E04E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8F817B35BAFF61F42268DDB185E086C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0999DCE1B7B6B1991C7BDDB185E09A83" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8F817B35BAFF61F42268DDB185E086C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0596927FDBD285B7CB6FDDB18690D4AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_4EA38563EF8AFA253DECDDB18690582F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0596927FDBD285B7CB6FDDB18690D4AD" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_4EA38563EF8AFA253DECDDB18690582F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B05BCB5ACDD99A640F361AED1B51F6E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_50E630C8526F1480814A1AED1B51EBAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B05BCB5ACDD99A640F361AED1B51F6E0" xlink:to="loc_us-gaap_InventoryNetAbstract_50E630C8526F1480814A1AED1B51EBAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B643DB3CEC915C700CBD1AED1B51B70F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_50E630C8526F1480814A1AED1B51EBAA" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B643DB3CEC915C700CBD1AED1B51B70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_304D69AC8C01C8AB795C1AED1B56352B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_50E630C8526F1480814A1AED1B51EBAA" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_304D69AC8C01C8AB795C1AED1B56352B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1289A404CE156E6797741AED1B56160C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_50E630C8526F1480814A1AED1B51EBAA" xlink:to="loc_us-gaap_InventoryNet_1289A404CE156E6797741AED1B56160C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrentAbstract" xlink:label="loc_us-gaap_InventoryNoncurrentAbstract_503C981818AF90CC1BE41AED1B562289" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B05BCB5ACDD99A640F361AED1B51F6E0" xlink:to="loc_us-gaap_InventoryNoncurrentAbstract_503C981818AF90CC1BE41AED1B562289" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_B8DF1CEF14A1FCE4F52C1AED1B5676B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_503C981818AF90CC1BE41AED1B562289" xlink:to="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_B8DF1CEF14A1FCE4F52C1AED1B5676B3" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_046D018F39CCDF837B9B1AED1B58708E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_503C981818AF90CC1BE41AED1B562289" xlink:to="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_046D018F39CCDF837B9B1AED1B58708E" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_4742B8D1103CBBCF31601AED1B588089" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_503C981818AF90CC1BE41AED1B562289" xlink:to="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_4742B8D1103CBBCF31601AED1B588089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_63601ABB42D3DFA40F001AED1B581013" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_503C981818AF90CC1BE41AED1B562289" xlink:to="loc_us-gaap_InventoryNoncurrent_63601ABB42D3DFA40F001AED1B581013" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_Inventory" xlink:label="loc_vnda_Inventory_5690D7731CFA3FDC43EB1B005B168F6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B05BCB5ACDD99A640F361AED1B51F6E0" xlink:to="loc_vnda_Inventory_5690D7731CFA3FDC43EB1B005B168F6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_E782C782453C8B91BC08DDB185C7B03F" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ScheduleOfInventoriesTableTextBlock" xlink:label="loc_vnda_ScheduleOfInventoriesTableTextBlock_07599768C8E20027F5D1DDB185C77317" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_E782C782453C8B91BC08DDB185C7B03F" xlink:to="loc_vnda_ScheduleOfInventoriesTableTextBlock_07599768C8E20027F5D1DDB185C77317" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1507C6587FC17D841742DDB1868B6D60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_5B80F9D3C3C7244CAE15DDB1868C77AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1507C6587FC17D841742DDB1868B6D60" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_5B80F9D3C3C7244CAE15DDB1868C77AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_EED24CEEB1C62B2E1C1443243B364334" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8000AE0B87AE688E5ABD43243B3666B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EED24CEEB1C62B2E1C1443243B364334" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8000AE0B87AE688E5ABD43243B3666B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_60F3AB56BFE827663A4043243B362714" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8000AE0B87AE688E5ABD43243B3666B0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_60F3AB56BFE827663A4043243B362714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0489029853320028B9B43243B3603C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_60F3AB56BFE827663A4043243B362714" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0489029853320028B9B43243B3603C0" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_SubleaseMember" xlink:label="loc_vnda_SubleaseMember_274BB45D2DC90202F5F043243B37B845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0489029853320028B9B43243B3603C0" xlink:to="loc_vnda_SubleaseMember_274BB45D2DC90202F5F043243B37B845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_775F928A9DF340589F8D43243B379EB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8000AE0B87AE688E5ABD43243B3666B0" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_775F928A9DF340589F8D43243B379EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_14787F1BABC56230576543243B370367" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_775F928A9DF340589F8D43243B379EB6" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_14787F1BABC56230576543243B370367" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_WashingtonDcLeaseMember" xlink:label="loc_vnda_WashingtonDcLeaseMember_98B4BB5B41899499A28D43243B37EFB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_14787F1BABC56230576543243B370367" xlink:to="loc_vnda_WashingtonDcLeaseMember_98B4BB5B41899499A28D43243B37EFB7" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_LondonLeaseMember" xlink:label="loc_vnda_LondonLeaseMember_AB55DB53D95075F78A1543243B389823" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_14787F1BABC56230576543243B370367" xlink:to="loc_vnda_LondonLeaseMember_AB55DB53D95075F78A1543243B389823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8000AE0B87AE688E5ABD43243B3666B0" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_21F2C3C4201C60464CA143243B38677C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_21F2C3C4201C60464CA143243B38677C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_DED5D0A6D129369EEE8043243B39A0AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_DED5D0A6D129369EEE8043243B39A0AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_007BB4888E071C7DDF2543243B39BAD1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:to="loc_us-gaap_OperatingLeaseCost_007BB4888E071C7DDF2543243B39BAD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_1063BC68BECBA1F2C96F43243B393077" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:to="loc_us-gaap_ShortTermLeaseCost_1063BC68BECBA1F2C96F43243B393077" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_OperatingLeaseNonLeaseComponentExpense" xlink:label="loc_vnda_OperatingLeaseNonLeaseComponentExpense_A82FBF89A17B61AF4A1243243B39854F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:to="loc_vnda_OperatingLeaseNonLeaseComponentExpense_A82FBF89A17B61AF4A1243243B39854F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_E132A5ECE8B22BB02B2843243B394327" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:to="loc_us-gaap_LeaseAndRentalExpense_E132A5ECE8B22BB02B2843243B394327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_7A1AB375A57A6A58756543243B39C046" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_88721DECA5B192CAF6F343243B381714" xlink:to="loc_us-gaap_OperatingLeasePayments_7A1AB375A57A6A58756543243B39C046" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_B398DCA1532C4BC9CF6FDDB185BC8C50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_B2FDECCA83338121DE34DDB185BCD123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B398DCA1532C4BC9CF6FDDB185BC8C50" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_B2FDECCA83338121DE34DDB185BCD123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0EA07D0450FB0F828B7FDDB185BDB7D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B398DCA1532C4BC9CF6FDDB185BC8C50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0EA07D0450FB0F828B7FDDB185BDB7D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_817EB457D52C312AF8C6DDB185BDFB90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B398DCA1532C4BC9CF6FDDB185BC8C50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_817EB457D52C312AF8C6DDB185BDFB90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_0E1AE4EA088C7A60A388DDB185BDBA50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B398DCA1532C4BC9CF6FDDB185BC8C50" xlink:to="loc_us-gaap_OperatingLeaseLiability_0E1AE4EA088C7A60A388DDB185BDBA50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4F39F6C2C8B9FD948612DDB185BD4152" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B398DCA1532C4BC9CF6FDDB185BC8C50" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4F39F6C2C8B9FD948612DDB185BD4152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8686012701A70C964631DDB185BE3BD9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B398DCA1532C4BC9CF6FDDB185BC8C50" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8686012701A70C964631DDB185BE3BD9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8C218FC599CCF26182411AED1B09D7A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8C218FC599CCF26182411AED1B09D7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3B53C929369DBD24B7731AED1B09CECA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3B53C929369DBD24B7731AED1B09CECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_23C6126F72AD071C44F01AED1B096688" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_23C6126F72AD071C44F01AED1B096688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C24A225CEE3E359CF8301AED1B096361" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C24A225CEE3E359CF8301AED1B096361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D4B76ADD7EA0EBBE15BE1AED1B0A22AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_D4B76ADD7EA0EBBE15BE1AED1B0A22AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0E819B7CA8C86C06CED1AED1B0A4DC4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0E819B7CA8C86C06CED1AED1B0A4DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C379B4F797D2D5AB28B51AED1B0AFE8D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C379B4F797D2D5AB28B51AED1B0AFE8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80239C7F8A69760A82231AED1B0AAA25" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_80239C7F8A69760A82231AED1B0AAA25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_315132AFCCAB1F5ED94E1AED1B0A4BAF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_OperatingLeaseLiability_315132AFCCAB1F5ED94E1AED1B0A4BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_00D4A9B120F50BE37C691AED1B0AFAB9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_00D4A9B120F50BE37C691AED1B0AFAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6FA4D3015BE29F6778C61AED1B0BF11B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07F53F97068993C375EC1AED1B09D8B7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6FA4D3015BE29F6778C61AED1B0BF11B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesMaturitiesUnderAsc840Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8F15D8FE19261DD56FBBDDB185A51256" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8F15D8FE19261DD56FBBDDB185A51256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_768E518709694CD8297BDDB185A5D30E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_768E518709694CD8297BDDB185A5D30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A6C4495B6463147D9E30DDB185A6EBA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_A6C4495B6463147D9E30DDB185A6EBA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_708E70510D41752784E1DDB185A61823" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_708E70510D41752784E1DDB185A61823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_A877317B6A578C3DD6ACDDB185A6CF41" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_A877317B6A578C3DD6ACDDB185A6CF41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_E2287A5FC3DFB472BCC2DDB185A6291B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_E2287A5FC3DFB472BCC2DDB185A6291B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_29F6ABE3CBD4C64280F9DDB185A65C47" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83A4B7E79072C52B885ADDB185A53E9B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_29F6ABE3CBD4C64280F9DDB185A65C47" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0873F9ED84A5055F2CBEDDB18590EB13" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock_755B3C934B1E47AFB1C0DDB185913FD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0873F9ED84A5055F2CBEDDB18590EB13" xlink:to="loc_vnda_ScheduleOfLeaseAssetsAndLiabilitiesTableTextBlock_755B3C934B1E47AFB1C0DDB185913FD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_81FAA33AF46422AA03BADDB185910F92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0873F9ED84A5055F2CBEDDB18590EB13" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_81FAA33AF46422AA03BADDB185910F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C3D25742157C7EBAADC0DDB18591F924" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0873F9ED84A5055F2CBEDDB18590EB13" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C3D25742157C7EBAADC0DDB18591F924" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_115181635241AF228F6BDDB1857B47B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_F77B741DF645D525062DDDB1857BBA21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_115181635241AF228F6BDDB1857B47B4" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_F77B741DF645D525062DDDB1857BBA21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DA4A407B5E5256F336DFDDB186C80E5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6F951442B103C0F40745DDB186C84E7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DA4A407B5E5256F336DFDDB186C80E5F" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6F951442B103C0F40745DDB186C84E7C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6DD5294220831094CF4F460CBD968D90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72DAAF0F9E9B2C54292E460CBD9708BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6DD5294220831094CF4F460CBD968D90" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72DAAF0F9E9B2C54292E460CBD9708BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_20F54A8851D44B17E583460CBD97D41E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72DAAF0F9E9B2C54292E460CBD9708BD" xlink:to="loc_us-gaap_InvestmentTypeAxis_20F54A8851D44B17E583460CBD97D41E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_FC9FF2FFEC97BBFFDC67460CBD971E29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_20F54A8851D44B17E583460CBD97D41E" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_FC9FF2FFEC97BBFFDC67460CBD971E29" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_CurrentInvestmentMember" xlink:label="loc_vnda_CurrentInvestmentMember_FAD29557E528EF1A8879460CBD98C495" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_FC9FF2FFEC97BBFFDC67460CBD971E29" xlink:to="loc_vnda_CurrentInvestmentMember_FAD29557E528EF1A8879460CBD98C495" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_NoncurrentInvestmentsMember" xlink:label="loc_vnda_NoncurrentInvestmentsMember_9E664A9EB3D49D3F7AD6460CBD98F8B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_FC9FF2FFEC97BBFFDC67460CBD971E29" xlink:to="loc_vnda_NoncurrentInvestmentsMember_9E664A9EB3D49D3F7AD6460CBD98F8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_66178E9717C2F38BD8C5460CBD98AA2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72DAAF0F9E9B2C54292E460CBD9708BD" xlink:to="loc_us-gaap_FinancialInstrumentAxis_66178E9717C2F38BD8C5460CBD98AA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0152EFFBE93842756F22460CBD98C941" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_66178E9717C2F38BD8C5460CBD98AA2D" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0152EFFBE93842756F22460CBD98C941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_FBA8844F03038D6D950F460CBD993F5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0152EFFBE93842756F22460CBD98C941" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_FBA8844F03038D6D950F460CBD993F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_F07C9F6D443B242BDDBB460CBD9C3CDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0152EFFBE93842756F22460CBD98C941" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_F07C9F6D443B242BDDBB460CBD9C3CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_99962DA907F3A868BD49460CBD9CE822" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0152EFFBE93842756F22460CBD98C941" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_99962DA907F3A868BD49460CBD9CE822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09B6C5237DF384B97FC0460CBD9C36AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72DAAF0F9E9B2C54292E460CBD9708BD" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09B6C5237DF384B97FC0460CBD9C36AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C3B9701C19501A86F6B9460CBD9C5098" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09B6C5237DF384B97FC0460CBD9C36AE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C3B9701C19501A86F6B9460CBD9C5098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7323715F706632E1A1C2460CBD9D539F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09B6C5237DF384B97FC0460CBD9C36AE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7323715F706632E1A1C2460CBD9D539F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_01103A98E07989A3DCDE460CBD9D753A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09B6C5237DF384B97FC0460CBD9C36AE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_01103A98E07989A3DCDE460CBD9D753A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D2526DEC4CBBB2DE11BF460CBD9DB814" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09B6C5237DF384B97FC0460CBD9C36AE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D2526DEC4CBBB2DE11BF460CBD9DB814" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C6FAEEAC2550F120EC93DDB186922E40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_1935F559E8339702164BDDB18692584B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C6FAEEAC2550F120EC93DDB186922E40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_1935F559E8339702164BDDB18692584B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4184F1CD418306E1EF48DDB18638B0C1" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_PublicOfferingOfCommonStockTextBlock" xlink:label="loc_vnda_PublicOfferingOfCommonStockTextBlock_AC43B0BE34E04737E536DDB18638E74C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4184F1CD418306E1EF48DDB18638B0C1" xlink:to="loc_vnda_PublicOfferingOfCommonStockTextBlock_AC43B0BE34E04737E536DDB18638E74C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/PublicOfferingOfCommonStockDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1434DF7F5698AC1F7CE1DDB186778659" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_C0CF9D06283D0BE47CDBDDB1867869AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1434DF7F5698AC1F7CE1DDB186778659" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_C0CF9D06283D0BE47CDBDDB1867869AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7128C25A991D163B921EDDB18678F923" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_C0CF9D06283D0BE47CDBDDB1867869AC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7128C25A991D163B921EDDB18678F923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1F8DBF7D79AA6D649F35DDB186785A87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7128C25A991D163B921EDDB18678F923" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1F8DBF7D79AA6D649F35DDB186785A87" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_PublicOfferingMember" xlink:label="loc_vnda_PublicOfferingMember_D52167CCB3EF28766D56DDB18678E09E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1F8DBF7D79AA6D649F35DDB186785A87" xlink:to="loc_vnda_PublicOfferingMember_D52167CCB3EF28766D56DDB18678E09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_146E05A044562A37613EDDB186794038" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1F8DBF7D79AA6D649F35DDB186785A87" xlink:to="loc_us-gaap_OverAllotmentOptionMember_146E05A044562A37613EDDB186794038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_BE8C2702CFF2A8870C6BDDB186799D80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_C0CF9D06283D0BE47CDBDDB1867869AC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_BE8C2702CFF2A8870C6BDDB186799D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DCFCA3D4F4CF75A3E010DDB18679EB61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_BE8C2702CFF2A8870C6BDDB186799D80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_DCFCA3D4F4CF75A3E010DDB18679EB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_49DD90F903C830DC354DDDB1867A670D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_BE8C2702CFF2A8870C6BDDB186799D80" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_49DD90F903C830DC354DDDB1867A670D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D3325092AB673215A669DDB1867A030C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_BE8C2702CFF2A8870C6BDDB186799D80" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D3325092AB673215A669DDB1867A030C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63390D21138B6D21E54CDDB1868DD8EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8D097B37248B935EB9B9DDB1868E93C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63390D21138B6D21E54CDDB1868DD8EE" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8D097B37248B935EB9B9DDB1868E93C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39E69F244E50A1A6C183DDB18578B6D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D427F2B891EB49485281DDB18578A8D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39E69F244E50A1A6C183DDB18578B6D4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D427F2B891EB49485281DDB18578A8D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4543F8A783899C3D4088DDB1857880AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39E69F244E50A1A6C183DDB18578B6D4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4543F8A783899C3D4088DDB1857880AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E15C260FA5C499EA274BDDB18578C912" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39E69F244E50A1A6C183DDB18578B6D4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E15C260FA5C499EA274BDDB18578C912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637585FE830BF669E96FDDB185798D36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39E69F244E50A1A6C183DDB18578B6D4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637585FE830BF669E96FDDB185798D36" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C25828AD87802FC1E911DDB186B0C805" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0C0279305CB7A3E7202DDB186B0E86A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C25828AD87802FC1E911DDB186B0C805" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0C0279305CB7A3E7202DDB186B0E86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9920DB28C9DF6E29B4B1DDB186B108BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0C0279305CB7A3E7202DDB186B0E86A" xlink:to="loc_us-gaap_AwardTypeAxis_9920DB28C9DF6E29B4B1DDB186B108BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67C1C73D51FAEFAB3D30DDB186B152E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9920DB28C9DF6E29B4B1DDB186B108BC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67C1C73D51FAEFAB3D30DDB186B152E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A50FF6C4446CE4D69313DDB186B14FBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67C1C73D51FAEFAB3D30DDB186B152E9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_A50FF6C4446CE4D69313DDB186B14FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B029D0BAA4ED4578C6EADDB186B14A3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0C0279305CB7A3E7202DDB186B0E86A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B029D0BAA4ED4578C6EADDB186B14A3C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodOne" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodOne_278D3C4F9C9750B40E9BDDB186B22C98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B029D0BAA4ED4578C6EADDB186B14A3C" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodOne_278D3C4F9C9750B40E9BDDB186B22C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE783C15473F1ABAE707DDB186B2FA9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B029D0BAA4ED4578C6EADDB186B14A3C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE783C15473F1ABAE707DDB186B2FA9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6EBF1308D2897DE1642CDDB186B2489E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B029D0BAA4ED4578C6EADDB186B14A3C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6EBF1308D2897DE1642CDDB186B2489E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0421D4913B6DB9787E75DDB186B21888" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B029D0BAA4ED4578C6EADDB186B14A3C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0421D4913B6DB9787E75DDB186B21888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7FCE5766D07B6D7D3C97DDB186B2D4D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B029D0BAA4ED4578C6EADDB186B14A3C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7FCE5766D07B6D7D3C97DDB186B2D4D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A8ADD4FE09499E87CDBDDB1861A0BB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C01879CC4B78B6F0E6A9DDB1861AB7D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A8ADD4FE09499E87CDBDDB1861A0BB2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C01879CC4B78B6F0E6A9DDB1861AB7D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_44820D4A8A8D801B07A7DDB1861BC7D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C01879CC4B78B6F0E6A9DDB1861AB7D0" xlink:to="loc_us-gaap_PlanNameAxis_44820D4A8A8D801B07A7DDB1861BC7D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_36721E7645BBE1AA5ADEDDB1861B412D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_44820D4A8A8D801B07A7DDB1861BC7D4" xlink:to="loc_us-gaap_PlanNameDomain_36721E7645BBE1AA5ADEDDB1861B412D" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_BD54EAE12587C4BE0317DDB1861C9FBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_36721E7645BBE1AA5ADEDDB1861B412D" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_BD54EAE12587C4BE0317DDB1861C9FBB" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_TwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixteenPlanMember_8467BDE245409DF8E3ABDDB1861C897E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_36721E7645BBE1AA5ADEDDB1861B412D" xlink:to="loc_vnda_TwoThousandSixteenPlanMember_8467BDE245409DF8E3ABDDB1861C897E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8263C8EFDD83E10E0B7DDDB1861CB070" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C01879CC4B78B6F0E6A9DDB1861AB7D0" xlink:to="loc_us-gaap_AwardTypeAxis_8263C8EFDD83E10E0B7DDDB1861CB070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50C1681501C5E6238211DDB1861C8C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8263C8EFDD83E10E0B7DDDB1861CB070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50C1681501C5E6238211DDB1861C8C4F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:label="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_40F6CCFA2A6BAAA1EE57DDB1861C096D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50C1681501C5E6238211DDB1861C8C4F" xlink:to="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_40F6CCFA2A6BAAA1EE57DDB1861C096D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DD0E4B2055CEB0C23971DDB1861D4B30" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C01879CC4B78B6F0E6A9DDB1861AB7D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DD0E4B2055CEB0C23971DDB1861D4B30" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_3694D9094E390DCE386CDDB1861DB537" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DD0E4B2055CEB0C23971DDB1861D4B30" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_3694D9094E390DCE386CDDB1861DB537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_703AC09CBCC7FE464704DDB1861DE8E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DD0E4B2055CEB0C23971DDB1861D4B30" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_703AC09CBCC7FE464704DDB1861DE8E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6C024AD6A0151CEB6C11DDB1861D8E54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DD0E4B2055CEB0C23971DDB1861D4B30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6C024AD6A0151CEB6C11DDB1861D8E54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60A822F79A9162EEA237DDB185F93708" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5B25ED1F4A4FFBB5313DDB185F9C987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60A822F79A9162EEA237DDB185F93708" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5B25ED1F4A4FFBB5313DDB185F9C987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5274AF2C91E426E84CBCDDB185FA7C05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5B25ED1F4A4FFBB5313DDB185F9C987" xlink:to="loc_us-gaap_AwardTypeAxis_5274AF2C91E426E84CBCDDB185FA7C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A236D193BA2232607C0DDDB185FA5F1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5274AF2C91E426E84CBCDDB185FA7C05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A236D193BA2232607C0DDDB185FA5F1D" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ServiceOptionAwardsMember" xlink:label="loc_vnda_ServiceOptionAwardsMember_CD57D18C9FB6E8038BC9DDB185FABF47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A236D193BA2232607C0DDDB185FA5F1D" xlink:to="loc_vnda_ServiceOptionAwardsMember_CD57D18C9FB6E8038BC9DDB185FABF47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5B25ED1F4A4FFBB5313DDB185F9C987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:label="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_79430D440CADF59D9ACFDDB185FBF084" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_79430D440CADF59D9ACFDDB185FBF084" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_4CDBAD6A0D0CC71457ADDDB185FB586E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_4CDBAD6A0D0CC71457ADDDB185FB586E" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_CAB1F5FF05843EF88BF7DDB185FB6A91" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_CAB1F5FF05843EF88BF7DDB185FB6A91" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_OptionAwardsVestingPeriodAfterCompletionOfOneYearOfService" xlink:label="loc_vnda_OptionAwardsVestingPeriodAfterCompletionOfOneYearOfService_138EF6C6564057ED3910DDB185FB3E55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_vnda_OptionAwardsVestingPeriodAfterCompletionOfOneYearOfService_138EF6C6564057ED3910DDB185FB3E55" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodDirectors" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodDirectors_4CCA10D7EBC146614371DDB185FC6ED6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodDirectors_4CCA10D7EBC146614371DDB185FC6ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9BB33AC99ACEE376B7E5DDB185FC510F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9BB33AC99ACEE376B7E5DDB185FC510F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_648A215379BBA1400D5BDDB185FC447E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_648A215379BBA1400D5BDDB185FC447E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82A6119A7B2B32968C77DDB185FCFF8B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82A6119A7B2B32968C77DDB185FCFF8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_08D77BCB3EA6E29BE9C6DDB185FD822E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E88CA13DF2D1CB75488DDB185FBF454" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_08D77BCB3EA6E29BE9C6DDB185FD822E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18F3775FA903F135659BDDB186BF928B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4AD33550745B2D87D639DDB186C06E45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18F3775FA903F135659BDDB186BF928B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4AD33550745B2D87D639DDB186C06E45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_33C1EB864F309B86C650DDB186C07869" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4AD33550745B2D87D639DDB186C06E45" xlink:to="loc_us-gaap_PlanNameAxis_33C1EB864F309B86C650DDB186C07869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E920266222E953E657E1DDB186C041C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_33C1EB864F309B86C650DDB186C07869" xlink:to="loc_us-gaap_PlanNameDomain_E920266222E953E657E1DDB186C041C2" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_5DD4C86B620067A0EAB4DDB186C04091" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_E920266222E953E657E1DDB186C041C2" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_5DD4C86B620067A0EAB4DDB186C04091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4AD33550745B2D87D639DDB186C06E45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5A0C2B3DF27F02AAA76BDDB186C1D0B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5A0C2B3DF27F02AAA76BDDB186C1D0B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B27632E675AA59E6A998DDB186C10A1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5A0C2B3DF27F02AAA76BDDB186C1D0B5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B27632E675AA59E6A998DDB186C10A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_359D2C3D9FB89F357C29DDB186C2DB75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5A0C2B3DF27F02AAA76BDDB186C1D0B5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_359D2C3D9FB89F357C29DDB186C2DB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_81AB4A9CB1AC2F9CF304DDB186C2F199" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5A0C2B3DF27F02AAA76BDDB186C1D0B5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_81AB4A9CB1AC2F9CF304DDB186C2F199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09F4C4DD8E0C764E9AECDDB186C2F7E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5A0C2B3DF27F02AAA76BDDB186C1D0B5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09F4C4DD8E0C764E9AECDDB186C2F7E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02C01477307A4D93556FDDB186C28622" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5A0C2B3DF27F02AAA76BDDB186C1D0B5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02C01477307A4D93556FDDB186C28622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_581060CF52B1E4E9A946DDB186C25483" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_581060CF52B1E4E9A946DDB186C25483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2299A69D3B72AB8ADD8FDDB186C20D10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2299A69D3B72AB8ADD8FDDB186C20D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43348F6FF2C82414AF43DDB186C3CDE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43348F6FF2C82414AF43DDB186C3CDE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_842BBE30CE02B4227D59DDB186C36374" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_842BBE30CE02B4227D59DDB186C36374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_04F2179533F9E934C32EDDB186C3CA6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_04F2179533F9E934C32EDDB186C3CA6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D9802414B8747E17076DDB186C32783" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D9802414B8747E17076DDB186C32783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B0485C575CF667965163DDB186C476E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B0485C575CF667965163DDB186C476E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ECD5AE339C67050A54DDDDB186C4891E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ECD5AE339C67050A54DDDDB186C4891E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2E9CE0A4543D95CED53EDDB186C4EF95" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4F3E6E0ACAA30B647B73DDB186C3497F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2E9CE0A4543D95CED53EDDB186C4EF95" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_130E3FCE965C05C3275FDDB186C465EB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_130E3FCE965C05C3275FDDB186C465EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8F009A374F66511567F6DDB186C4714A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_130E3FCE965C05C3275FDDB186C465EB" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8F009A374F66511567F6DDB186C4714A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1834448E2272FD5B26ABDDB186C51EB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_130E3FCE965C05C3275FDDB186C465EB" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1834448E2272FD5B26ABDDB186C51EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3A5A3457E2D308284403DDB186C5ED66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_130E3FCE965C05C3275FDDB186C465EB" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3A5A3457E2D308284403DDB186C5ED66" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_F908D3AE7ABA93E00DFBDDB186C5DD72" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72ADCFB4258C1488CC28DDB186C15545" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_F908D3AE7ABA93E00DFBDDB186C5DD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_152B59B8B32F793DE574DDB186C5F8BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_F908D3AE7ABA93E00DFBDDB186C5DD72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_152B59B8B32F793DE574DDB186C5F8BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ACEE965DAB034E17A02CDDB186C5E17F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_F908D3AE7ABA93E00DFBDDB186C5DD72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ACEE965DAB034E17A02CDDB186C5E17F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_960231B1B03AD8FF3BA9DDB186C68E5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_F908D3AE7ABA93E00DFBDDB186C5DD72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_960231B1B03AD8FF3BA9DDB186C68E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_13C896115A606D93252CDDB186C6A431" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_F908D3AE7ABA93E00DFBDDB186C5DD72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_13C896115A606D93252CDDB186C6A431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_CFC88D6A8B971D1693CDDDB186C68791" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_F908D3AE7ABA93E00DFBDDB186C5DD72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_CFC88D6A8B971D1693CDDDB186C68791" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69407548A55268B9F7F0DDB1867011FC" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_B9EAE030FC1B71514E8BDDB18670D37B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69407548A55268B9F7F0DDB1867011FC" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_B9EAE030FC1B71514E8BDDB18670D37B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_86D8D2F821797FED02C3DDB186703231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_B9EAE030FC1B71514E8BDDB18670D37B" xlink:to="loc_us-gaap_AwardTypeAxis_86D8D2F821797FED02C3DDB186703231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14BBA181CBA293B589AADDB186714E8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_86D8D2F821797FED02C3DDB186703231" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14BBA181CBA293B589AADDB186714E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CCE88AE826C5765773B0DDB186711010" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14BBA181CBA293B589AADDB186714E8E" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_CCE88AE826C5765773B0DDB186711010" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_2A1C79A7E1E436EBEBC6DDB18671C509" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_B9EAE030FC1B71514E8BDDB18670D37B" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_2A1C79A7E1E436EBEBC6DDB18671C509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86C2448A06B2F426D5FDDDB1867135B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_2A1C79A7E1E436EBEBC6DDB18671C509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86C2448A06B2F426D5FDDDB1867135B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_232795561FA4B0C01FA5DDB186721C38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86C2448A06B2F426D5FDDDB1867135B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_232795561FA4B0C01FA5DDB186721C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8A399906F71E5F926777DDB18672A7F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86C2448A06B2F426D5FDDDB1867135B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8A399906F71E5F926777DDB18672A7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B2ACBAE88CA42621A0B9DDB18672A6E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86C2448A06B2F426D5FDDDB1867135B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B2ACBAE88CA42621A0B9DDB18672A6E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7FFDBCD59DAF18CF7B5BDDB18672CA9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86C2448A06B2F426D5FDDDB1867135B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7FFDBCD59DAF18CF7B5BDDB18672CA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2F3AAAB07D5968DC8987DDB18673A9F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86C2448A06B2F426D5FDDDB1867135B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2F3AAAB07D5968DC8987DDB18673A9F2" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_A5C1B21E2EDF9949D170DDB18673A1F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_2A1C79A7E1E436EBEBC6DDB18671C509" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_A5C1B21E2EDF9949D170DDB18673A1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0535F50468DC5645FD5ADDB18673E9EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_A5C1B21E2EDF9949D170DDB18673A1F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0535F50468DC5645FD5ADDB18673E9EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_545E68F310E4F2AF0186DDB18673D9AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_A5C1B21E2EDF9949D170DDB18673A1F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_545E68F310E4F2AF0186DDB18673D9AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F7515236CC01635AF732DDB18673F8E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_A5C1B21E2EDF9949D170DDB18673A1F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F7515236CC01635AF732DDB18673F8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_68CBB24CD6D903A4ED37DDB18674A8AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_A5C1B21E2EDF9949D170DDB18673A1F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_68CBB24CD6D903A4ED37DDB18674A8AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F01E120AB0D5957D368CDDB18674C1E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_A5C1B21E2EDF9949D170DDB18673A1F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F01E120AB0D5957D368CDDB18674C1E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_546E2444F06AB7DCFE0DDDB18655A03B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0E264810C30238B7C718DDB18655F22F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_546E2444F06AB7DCFE0DDDB18655A03B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0E264810C30238B7C718DDB18655F22F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AC6DFDF773D2EFEBFE97DDB18656AD4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_546E2444F06AB7DCFE0DDDB18655A03B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AC6DFDF773D2EFEBFE97DDB18656AD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_99554192C14886793EE0DDB1865693EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_546E2444F06AB7DCFE0DDDB18655A03B" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_99554192C14886793EE0DDB1865693EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4F5B50DF7FEDEE044DA0DDB186564DF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_546E2444F06AB7DCFE0DDDB18655A03B" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4F5B50DF7FEDEE044DA0DDB186564DF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1C258E95063DEFE51B42DDB185F147BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D747687C625C3935D1E7DDB185F16F40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1C258E95063DEFE51B42DDB185F147BB" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D747687C625C3935D1E7DDB185F16F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B8F8C921FD130305752ADDB185F140D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D747687C625C3935D1E7DDB185F16F40" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B8F8C921FD130305752ADDB185F140D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83154CA09451B8E97FC1DDB185F29DE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B8F8C921FD130305752ADDB185F140D7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83154CA09451B8E97FC1DDB185F29DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A6266F084F40613AC710DDB185F29F26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83154CA09451B8E97FC1DDB185F29DE5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A6266F084F40613AC710DDB185F29F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_67B886D1B5C6B4C308C7DDB185F27EB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83154CA09451B8E97FC1DDB185F29DE5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_67B886D1B5C6B4C308C7DDB185F27EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BDF8254E7B05E9823A9EDDB185F20A98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D747687C625C3935D1E7DDB185F16F40" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BDF8254E7B05E9823A9EDDB185F20A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_31551BE57D451BD74F05DDB185F2847D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BDF8254E7B05E9823A9EDDB185F20A98" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_31551BE57D451BD74F05DDB185F2847D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8F657FD371B5ADBE1805DDB1854ED52E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_BE01FB2D2028D1B5DF10DDB1854EFA5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8F657FD371B5ADBE1805DDB1854ED52E" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_BE01FB2D2028D1B5DF10DDB1854EFA5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8E84B590BCA43BDBAAD743510CF1D50A" xlink:type="locator" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_D0F23350F161BBF675C343510CF11E48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8E84B590BCA43BDBAAD743510CF1D50A" xlink:to="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_D0F23350F161BBF675C343510CF11E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_461C0670F1AE577C261243510CF1324A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_D0F23350F161BBF675C343510CF11E48" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_461C0670F1AE577C261243510CF1324A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_603FFF09A70035D316D343510CF1D429" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_461C0670F1AE577C261243510CF1324A" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_603FFF09A70035D316D343510CF1D429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C514FFBEE4644A77B11C43510CF19D4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_603FFF09A70035D316D343510CF1D429" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_C514FFBEE4644A77B11C43510CF19D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_C088583EB82ECAA081E243510CF11108" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_603FFF09A70035D316D343510CF1D429" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_C088583EB82ECAA081E243510CF11108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5DC1899C6745D7CDEAB443510CF1ADF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_D0F23350F161BBF675C343510CF11E48" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5DC1899C6745D7CDEAB443510CF1ADF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9BC5690A4952DFE79C3A43510CF1CB0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5DC1899C6745D7CDEAB443510CF1ADF5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9BC5690A4952DFE79C3A43510CF1CB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_A12102EF3A02FB3C9D7B43510CF15AF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9BC5690A4952DFE79C3A43510CF1CB0F" xlink:to="loc_us-gaap_SalesRevenueNetMember_A12102EF3A02FB3C9D7B43510CF15AF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_8FC5CDD193E1BC73492743510CF1D035" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9BC5690A4952DFE79C3A43510CF1CB0F" xlink:to="loc_us-gaap_AccountsReceivableMember_8FC5CDD193E1BC73492743510CF1D035" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_DF1BB22D3586CFBBF3D543510CF1303B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_D0F23350F161BBF675C343510CF11E48" xlink:to="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_DF1BB22D3586CFBBF3D543510CF1303B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_NumberOfMajorCustomersAccountedForRevenue" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_4D1B0F675F0EDF2966CB43510CF19743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_DF1BB22D3586CFBBF3D543510CF1303B" xlink:to="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_4D1B0F675F0EDF2966CB43510CF19743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_35A1A2F586DD2EB34BF243510CF19B32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_DF1BB22D3586CFBBF3D543510CF1303B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_35A1A2F586DD2EB34BF243510CF19B32" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_97D0172A0FB9D2C27ED943510CF1DC68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_DF1BB22D3586CFBBF3D543510CF1303B" xlink:to="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_97D0172A0FB9D2C27ED943510CF1DC68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_EBF6A4E7817DB154EF6843510CF14FB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_DF1BB22D3586CFBBF3D543510CF1303B" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_EBF6A4E7817DB154EF6843510CF14FB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CF4905E2C8FEFAC32105DDB186858D7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E1A22673E294A47E25DDDDB18686F738" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CF4905E2C8FEFAC32105DDB186858D7C" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E1A22673E294A47E25DDDDB18686F738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8AB6F9EC92E53E2DB76BDDB18686E591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E1A22673E294A47E25DDDDB18686F738" xlink:to="loc_srt_ProductOrServiceAxis_8AB6F9EC92E53E2DB76BDDB18686E591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E640E35EA09A5033E7F2DDB18686E752" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8AB6F9EC92E53E2DB76BDDB18686E591" xlink:to="loc_srt_ProductsAndServicesDomain_E640E35EA09A5033E7F2DDB18686E752" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_F8D3DDEC382604500F44DDB186869DF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E640E35EA09A5033E7F2DDB18686E752" xlink:to="loc_vnda_HetliozMember_F8D3DDEC382604500F44DDB186869DF8" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_57FF1F1517FB48BA81A4DDB186877890" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E640E35EA09A5033E7F2DDB18686E752" xlink:to="loc_vnda_FanaptMember_57FF1F1517FB48BA81A4DDB186877890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_19FCA447B4E8EF50FA30DDB18687E987" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E1A22673E294A47E25DDDDB18686F738" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_19FCA447B4E8EF50FA30DDB18687E987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_486AFEA63BBFF88D0352DDB186878CAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_19FCA447B4E8EF50FA30DDB18687E987" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_486AFEA63BBFF88D0352DDB186878CAC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C9E043385B75B3D25A33DDB1863584A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C9E043385B75B3D25A33DDB1863584A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_7C891B67E3020D92EDB2DDB18635A2DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_UseOfEstimates_7C891B67E3020D92EDB2DDB18635A2DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1E58C42AE331A330E2B0DDB18635E90D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1E58C42AE331A330E2B0DDB18635E90D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_DAA409E5CB9E72D93AF4DDB186350E4C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_DAA409E5CB9E72D93AF4DDB186350E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9C21E8BAE7307679F10ADDB18635C81F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9C21E8BAE7307679F10ADDB18635C81F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0EAC75976CD6693D12CBDDB18636DA19" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0EAC75976CD6693D12CBDDB18636DA19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_EED5C1E5580B2DED31B7DDB18636A03F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_EED5C1E5580B2DED31B7DDB18636A03F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_F7340AD2C389243B6798DDB18636BD61" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_F7340AD2C389243B6798DDB18636BD61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2793EA200EEC2A4F3000DDB18636AC73" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_779854DB01F73D16BD3BDDB18634711C" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2793EA200EEC2A4F3000DDB18636AC73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E4B55F77927A37742D6FDDB185961899" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_F1A4A0D6B2D0A3AA63A2DDB18596ABD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E4B55F77927A37742D6FDDB185961899" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_F1A4A0D6B2D0A3AA63A2DDB18596ABD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AB5E7ACA8B4EE65BEB9FDDB18597F4F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_F1A4A0D6B2D0A3AA63A2DDB18596ABD1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AB5E7ACA8B4EE65BEB9FDDB18597F4F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_E735303BF126761ECB28DDB185978C06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AB5E7ACA8B4EE65BEB9FDDB18597F4F2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_E735303BF126761ECB28DDB185978C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_68F16D055F63B6F2ED02DDB185974453" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_E735303BF126761ECB28DDB185978C06" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_68F16D055F63B6F2ED02DDB185974453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5F07FF30057427743F68DDB18598B66F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_F1A4A0D6B2D0A3AA63A2DDB18596ABD1" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5F07FF30057427743F68DDB18598B66F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_02FAFD1D9EFEF4B42BB4DDB185987987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5F07FF30057427743F68DDB18598B66F" xlink:to="loc_us-gaap_OperatingLeaseLiability_02FAFD1D9EFEF4B42BB4DDB185987987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_162EA6688F3FE755BDD0DDB18598F966" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5F07FF30057427743F68DDB18598B66F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_162EA6688F3FE755BDD0DDB18598F966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6B2B1ED13298C51CDE55DDB185993D0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5F07FF30057427743F68DDB18598B66F" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6B2B1ED13298C51CDE55DDB185993D0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesSupplementalCashFlowsInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3532540D1A8330562A57DDB186A1C5FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_465105899D4A01473094DDB186A1C9CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3532540D1A8330562A57DDB186A1C5FE" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_465105899D4A01473094DDB186A1C9CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_F061B077236FEE56E851DDB186A172AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_465105899D4A01473094DDB186A1C9CF" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_F061B077236FEE56E851DDB186A172AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_203D5FE11CA174C74C5ADDB186A278FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_F061B077236FEE56E851DDB186A172AB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_203D5FE11CA174C74C5ADDB186A278FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8088C906904D339C8DF5DDB186A2C0B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_203D5FE11CA174C74C5ADDB186A278FD" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8088C906904D339C8DF5DDB186A2C0B1" xlink:type="arc" />
    <link:loc xlink:href="vnda-20190630.xsd#vnda_NoncurrentInventoryAndOtherMember" xlink:label="loc_vnda_NoncurrentInventoryAndOtherMember_DD64EAA7456ED1A704F1DDB186A2C6E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_203D5FE11CA174C74C5ADDB186A278FD" xlink:to="loc_vnda_NoncurrentInventoryAndOtherMember_DD64EAA7456ED1A704F1DDB186A2C6E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6FDF92755A20F1A88D4BDDB186A22591" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_465105899D4A01473094DDB186A1C9CF" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6FDF92755A20F1A88D4BDDB186A22591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1802BA6A2DE9586DD41CDDB186A242CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6FDF92755A20F1A88D4BDDB186A22591" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1802BA6A2DE9586DD41CDDB186A242CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_E0041996BE2902016CD3DDB186A30BEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6FDF92755A20F1A88D4BDDB186A22591" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_E0041996BE2902016CD3DDB186A30BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_299E8E798998226480C3DDB186A3F82C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_E0041996BE2902016CD3DDB186A30BEF" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_299E8E798998226480C3DDB186A3F82C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50E9A1921924C05C609FDDB186A31C59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6FDF92755A20F1A88D4BDDB186A22591" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50E9A1921924C05C609FDDB186A31C59" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_658B2D345DB098A710C9DDB18550C46E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_E2B9A9DC300008197920DDB18550D500" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_658B2D345DB098A710C9DDB18550C46E" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_E2B9A9DC300008197920DDB18550D500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4D9BEA9EFFB3F9E60C6CDDB18550F3A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_658B2D345DB098A710C9DDB18550C46E" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4D9BEA9EFFB3F9E60C6CDDB18550F3A9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/Tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_827AA68232559C771A00DDB185E36999" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C6B613BA4DC2CD9987BBDDB185E30ACB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_827AA68232559C771A00DDB185E36999" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C6B613BA4DC2CD9987BBDDB185E30ACB" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>